John G Cleland

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3100027/publications.pdf Version: 2024-02-01

| | | 293 | 195 |
|----------|----------------|--------------|----------------|
| 1,098 | 121,522 | 139 | 315 |
| papers | citations | h-index | g-index |
| | | | |
| | | | |
| 11 | | | 610.40 |
| 1177 | 1177 | 1177 | 61049 |
| all docs | docs citations | times ranked | citing authors |
| | | | |

| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 1 | 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2016, 37, 2129-2200. | 1.0 | 13,008 |
| 2 | 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 2018, 39, 3021-3104. | 1.0 | 6,826 |
| 3 | The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure. New England Journal of Medicine, 2005, 352, 1539-1549. | 13.9 | 5,656 |
| 4 | 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726. | 1.0 | 5,558 |
| 5 | 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2016, 18, 891-975. | 2.9 | 5,272 |
| 6 | 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal, 2013, 34, 2281-2329. | 1.0 | 2,176 |
| 7 | Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). European Heart Journal, 2005, 26, 1115-1140. | 1.0 | 1,986 |
| 8 | Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet, The, 2003, 362, 7-13. | 6.3 | 1,664 |
| 9 | Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet, The, 2002, 360, 196-202. | 6.3 | 1,621 |
| 10 | Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 2019, 381, 1609-1620. | 13.9 | 1,485 |
| 11 | Rosuvastatin in Older Patients with Systolic Heart Failure. New England Journal of Medicine, 2007, 357, 2248-2261. | 13.9 | 1,330 |
| 12 | The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal, 2006, 27, 2338-2345. | 1.0 | 1,280 |
| 13 | beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ: British Medical Journal, 1999, 318, 1730-1737. | 2.4 | 1,211 |
| 14 | The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. European Heart Journal, 2003, 24, 442-463. | 1.0 | 1,154 |
| 15 | Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure. Circulation, 1999, 100, 2312-2318. | 1.6 | 1,031 |
| 16 | 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace, 2013, 15, 1070-1118. | 0.7 | 908 |
| 17 | Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance. Are they interchangeable?. European Heart Journal, 2000, 21, 1387-1396. | 1.0 | 838 |
| 18 | 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131. | 2.9 | 820 |

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Family planning: the unfinished agenda. Lancet, The, 2006, 368, 1810-1827. | 6.3 | 812 |
| 20 | Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet, The, 2018, 391, 572-580. | 6.3 | 808 |
| 21 | Atrial fibrillation management: a prospective survey in ESC Member Countries. European Heart Journal, 2005, 26, 2422-2434. | 1.0 | 770 |
| 22 | The EuroHeart Failure Survey programme—a survey on the quality of care among patients with heart failure in Europe Part 2: treatment. European Heart Journal, 2003, 24, 464-474. | 1.0 | 711 |
| 23 | State of the art: Using natriuretic peptide levels in clinical practice. European Journal of Heart Failure, 2008, 10, 824-839. | 2.9 | 691 |
| 24 | Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in Collaboration with the European Heart Rhythm Association. European Heart Journal, 2007, 28, 2256-2295. | 1.0 | 677 |
| 25 | Noninvasive Home Telemonitoring for Patients With Heart Failure at High Risk of Recurrent Admission and Death. Journal of the American College of Cardiology, 2005, 45, 1654-1664. | 1.2 | 620 |
| 26 | Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. European Journal of Heart Failure, 2010, 12, 423-433. | 2.9 | 593 |
| 27 | Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. European Heart Journal, 2006, 27, 1928-1932. | 1.0 | 586 |
| 28 | Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. European Heart Journal, 2005, 26, 1303-1308. | 1.0 | 564 |
| 29 | Telemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and meta-analysis. BMJ: British Medical Journal, 2007, 334, 942. | 2.4 | 537 |
| 30 | The prevalence of abnormal glucose regulation in patients with coronary artery disease across EuropeThe Euro Heart Survey on diabetes and the heart. European Heart Journal, 2004, 25, 1880-1890. | 1.0 | 532 |
| 31 | Worsening Renal Function and Prognosis in Heart Failure: Systematic Review and Meta-Analysis. Journal of Cardiac Failure, 2007, 13, 599-608. | 0.7 | 527 |
| 32 | Contraception and health. Lancet, The, 2012, 380, 149-156. | 6.3 | 527 |
| 33 | Mitochondrial function as a therapeutic target in heart failure. Nature Reviews Cardiology, 2017, 14, 238-250. | 6.1 | 525 |
| 34 | Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet, The, 2002, 360, 1631-1639. | 6.3 | 493 |
| 35 | Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 1169-1186. | 2.9 | 490 |
| 36 | Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet, The, 2014, 384, 2235-2243. | 6.3 | 475 |

| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Rolofylline, an Adenosine A ₁ â^`Receptor Antagonist, in Acute Heart Failure. New England Journal of Medicine, 2010, 363, 1419-1428. | 13.9 | 473 |
| 38 | Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. European Journal of Heart Failure, 2019, 21, 715-731. | 2.9 | 446 |
| 39 | Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. European Heart Journal, 2018, 39, 26-35. | 1.0 | 426 |
| 40 | An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. European Heart Journal, 2013, 34, 3547-3556. | 1.0 | 410 |
| 41 | Occupation and risk of severe COVID-19: prospective cohort study of 120 075 UK Biobank participants. Occupational and Environmental Medicine, 2021, 78, 307-314. | 1.3 | 402 |
| 42 | Contraception in historical and global perspective. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2009, 23, 165-176. | 1.4 | 398 |
| 43 | Structured telephone support or telemonitoring programmes for patients with chronic heart failure. , 2010, , CD007228. | | 389 |
| 44 | The Warfarin/Aspirin study in heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. American Heart Journal, 2004, 148, 157-164. | 1.2 | 387 |
| 45 | Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors. European Heart Journal, 2020, 41, 1810-1817. | 1.0 | 381 |
| 46 | Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. New England Journal of Medicine, 2021, 384, 105-116. | 13.9 | 381 |
| 47 | Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet, The, 2019, 393, 61-73. | 6.3 | 379 |
| 48 | Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure. Circulation, 2009, 119, 1616-1624. | 1.6 | 370 |
| 49 | Declining Risk of Sudden Death in Heart Failure. New England Journal of Medicine, 2017, 377, 41-51. | 13.9 | 355 |
| 50 | Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients With Acute Heart Failure. JAMA - Journal of the American Medical Association, 2007, 298, 2009. | 3.8 | 330 |
| 51 | Which components of heart failure programmes are effective? A systematic review and metaâ€analysis of the outcomes of structured telephone support or telemonitoring as the primary component of chronic heart failure management in 8323 patients: Abridged Cochrane Review. European Journal of Heart Failure. 2011, 13, 1028-1040. | 2.9 | 319 |
| 52 | Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. European Heart Journal, 2004, 25, 1214-1220. | 1.0 | 315 |
| 53 | Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet, The, 2003, 362, 14-21. | 6.3 | 302 |
| 54 | 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Heart Rhythm, 2012, 9, 1524-1576. | 0.3 | 300 |

| # | Article | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. European Heart Journal, 2017, 38, 1883-1890. | 1.0 | 299 |
| 56 | Acute Coronary Findings at Autopsy in Heart Failure Patients With Sudden Death. Circulation, 2000, 102, 611-616. | 1.6 | 298 |
| 57 | The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet, The, 2011, 378, 676-683. | 6.3 | 295 |
| 58 | A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. European Heart Journal, 2011, 32, 1065-1076. | 1.0 | 292 |
| 59 | Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. European Journal of Heart Failure, 2006, 8, 105-110. | 2.9 | 282 |
| 60 | The CARE-HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end-points. European Journal of Heart Failure, 2001, 3, 481-489. | 2.9 | 279 |
| 61 | Diuretic response in acute heart failure: clinical characteristics and prognostic significance. European Heart Journal, 2014, 35, 1284-1293. | 1.0 | 276 |
| 62 | 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Revista Espanola De Cardiologia (English Ed), 2016, 69, 1167. | 0.4 | 274 |
| 63 | The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. European Journal of Heart Failure, 2002, 4, 515-529. | 2.9 | 268 |
| 64 | Developing Therapies for Heart Failure WithÂPreservedÂEjection Fraction. JACC: Heart Failure, 2014, 2, 97-112. | 1.9 | 267 |
| 65 | The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. European Heart Journal, 2005, 26, 2238-2244. | 1.0 | 266 |
| 66 | Association Between Midwall Late Gadolinium Enhancement and Sudden Cardiac Death in Patients With Dilated Cardiomyopathy and Mild and Moderate Left Ventricular Systolic Dysfunction. Circulation, 2017, 135, 2106-2115. | 1.6 | 265 |
| 67 | Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. New England Journal of Medicine, 2018, 379, 1332-1342. | 13.9 | 265 |
| 68 | Prediction of Mode of Death in Heart Failure. Circulation, 2007, 116, 392-398. | 1.6 | 261 |
| 69 | The heart failure epidemic: exactly how big is it?. European Heart Journal, 2001, 22, 623-626. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: | 1.0 | 259 |
| 70 | implant and follow-up recommendations and management: A registered branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society; and in collaboration with the Heart Failure Society of America (HFSA), the American Society of Echocardiography (ASE), the American Heart Association (AHA), the European Association of Echocardiography (EAE) of the ESC and the Heart | | |
| | | | |

| # | Article | IF | CITATIONS |
|----|--|-------------------|---------------|
| 73 | Losartan in Heart Failure. Circulation, 1995, 91, 691-697. | 1.6 | 246 |
| 74 | Structured telephone support or non-invasive telemonitoring for patients with heart failure. The Cochrane Library, 2015, 2015, CD007228. | 1.5 | 239 |
| 75 | A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE) Tj ETQq1 | 1 0.784314 6.3 | 1 rgBT/Overio |
| 76 | Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 1304-1317. | 2.6 | 232 |
| 77 | Reliability of reporting left ventricular systolic function by echocardiography: A systematic review of 3 methods. American Heart Journal, 2003, 146, 388-397. | 1.2 | 230 |
| 78 | Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet, The, 2016, 388, 2895-2903. | 6.3 | 229 |
| 79 | Effect of Cardiac Resynchronization on the Incidence of Atrial Fibrillation in Patients With Severe Heart Failure. Circulation, 2006, 114, 18-25. | 1.6 | 225 |
| 80 | Improving care for patients with acute heart failure: before, during and after hospitalization. ESC Heart Failure, 2014, 1, 110-145. | 1.4 | 222 |
| 81 | Longitudinal ventricular function: normal values of atrioventricular annular and myocardial velocities measured with quantitative two-dimensional color doppler tissue imaging. Journal of the American Society of Echocardiography, 2003, 16, 906-921. | 1.2 | 219 |
| 82 | Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction. Circulation: Heart Failure, 2011, 4, 569-577. | 1.6 | 219 |
| 83 | A systematic review of telemonitoring for the management of heart failure. European Journal of Heart Failure, 2003, 5, 583-590. | 2.9 | 216 |
| 84 | The European cardiac resynchronization therapy survey. European Heart Journal, 2009, 30, 2450-2460. | 1.0 | 215 |
| 85 | The TORCH (TOwards a Revolution in COPD Health) survival study protocol: Fig. 1.—. European Respiratory Journal, 2004, 24, 206-210. | 3.1 | 209 |
| 86 | Chronic heart failure and micronutrients. Journal of the American College of Cardiology, 2001, 37, 1765-1774. | 1.2 | 208 |
| 87 | Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. European Heart Journal, 2006, 27, 569-581. | 1.0 | 203 |
| 88 | Association of galectinâ€3 and fibrosis markers with longâ€ŧerm cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CAREâ€HF (Cardiac Resynchronization in Heart Failure) trial. European Journal of Heart Failure, 2012, 14, 74-81. | 2.9 | 203 |
| 89 | Surface electrocardiogram to predict outcome in candidates for cardiac resynchronization therapy: a subâ€analysis of the CAREâ€HF trial. European Journal of Heart Failure, 2009, 11, 699-705. | 2.9 | 202 |
| 90 | Reduced Alveolar–Capillary Membrane Diffusing Capacity in Chronic Heart Failure. Circulation, 1995, 91, 2769-2774. | 1.6 | 202 |

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. European Journal of Heart Failure, 2004, 6, 501-508. | 2.9 | 201 |
| 92 | The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. European Heart Journal, 2006, 27, 1440-1446. | 1.0 | 201 |
| 93 | Plasma Concentration of Amino-Terminal Pro-Brain Natriuretic Peptide in Chronic Heart Failure: Prediction of Cardiovascular Events and Interaction With the Effects of Rosuvastatin. Journal of the American College of Cardiology, 2009, 54, 1850-1859. | 1.2 | 200 |
| 94 | Identifying Pathophysiological Mechanisms in Heart Failure WithÂReduced Versus Preserved EjectionÂFraction. Journal of the American College of Cardiology, 2018, 72, 1081-1090. | 1.2 | 199 |
| 95 | Heart Rate and Rhythm and the BenefitÂofÂBeta-Blockers in PatientsÂWithÂHeart Failure. Journal of the American College of Cardiology, 2017, 69, 2885-2896. | 1.2 | 198 |
| 96 | ACC/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Chronic Heart Failure. Circulation, 2005, 112, 1888-1916. | 1.6 | 194 |
| 97 | Acute Treatment With Omecamtiv Mecarbil to Increase Contractility inÂAcuteÂHeart Failure. Journal of the American College of Cardiology, 2016, 67, 1444-1455. | 1.2 | 191 |
| 98 | Outcome in Dilated Cardiomyopathy Related to the Extent, Location, andÂPattern of Late Gadolinium Enhancement. JACC: Cardiovascular Imaging, 2019, 12, 1645-1655. | 2.3 | 187 |
| 99 | Risk stratification in chronic heart failure. European Heart Journal, 1998, 19, 696-710. | 1.0 | 186 |
| 100 | Predicting the Long-Term Effects of Cardiac Resynchronization Therapy on Mortality From Baseline Variables and the Early Response. Journal of the American College of Cardiology, 2008, 52, 438-445. | 1.2 | 186 |
| 101 | Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. European Heart Journal, 2007, 28, 2208-2216. | 1.0 | 184 |
| 102 | Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. European Journal of Heart Failure, 2017, 19, 627-634. | 2.9 | 183 |
| 103 | Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. European Journal of Heart Failure, 2013, 15, 1082-1094. | 2.9 | 182 |
| 104 | Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 272-285. | 2.9 | 182 |
| 105 | The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study. European Journal of Heart Failure, 2005, 7, 243-251. | 2.9 | 180 |
| 106 | Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. European Heart Journal, 2014, 35, 2468-2476. | 1.0 | 179 |
| 107 | Is the prognosis of heart failure improving?. European Journal of Heart Failure, 1999, 1, 229-241. | 2.9 | 175 |
| 108 | Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. European Heart Journal, 2013, 34, 1489-1497. | 1.0 | 175 |

| # | Article | IF | CITATIONS |
|-----|--|------|-----------|
| 109 | Effects of Serelaxin in Patients with Acute Heart Failure. New England Journal of Medicine, 2019, 381, 716-726. | 13.9 | 174 |
| 110 | Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease. Nature Medicine, 2019, 25, 1753-1760. | 15.2 | 174 |
| 111 | Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. European Heart Journal, 2005, 26, 2706-2713. | 1.0 | 172 |
| 112 | The clinical significance of interleukinâ€6 in heart failure: results from the BIOSTATâ€CHF study. European Journal of Heart Failure, 2019, 21, 965-973. | 2.9 | 172 |
| 113 | Personalizing Risk Stratification for Sudden Death in Dilated Cardiomyopathy. Circulation, 2017, 136, 215-231. | 1.6 | 171 |
| 114 | Symptoms in Patients With Heart Failure are Prognostic Predictors: Insights From COMET. Journal of Cardiac Failure, 2005, 11, 288-292. | 0.7 | 168 |
| 115 | Longâ€ŧerm left ventricular reverse remodelling with cardiac resynchronization therapy: results from the CAREâ€HF trial. European Journal of Heart Failure, 2009, 11, 480-488. | 2.9 | 167 |
| 116 | Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie?. European Heart Journal, 2020, 41, 1249-1257. | 1.0 | 167 |
| 117 | Sarcopenia in patients with heart failure with preserved ejection fraction: Impact on muscle strength, exercise capacity and quality of life. International Journal of Cardiology, 2016, 222, 41-46. | 0.8 | 166 |
| 118 | Prevalence and Prognostic Significance of Malnutrition Using 3 Scoring Systems Among Outpatients With Heart Failure. JACC: Heart Failure, 2018, 6, 476-486. | 1.9 | 166 |
| 119 | The Heart Failure Revascularisation Trial (HEART). European Journal of Heart Failure, 2011, 13, 227-233. | 2.9 | 164 |
| 120 | Signature of circulating <scp>microRNAs</scp> in patients with acute heart failure. European Journal of Heart Failure, 2016, 18, 414-423. | 2.9 | 162 |
| 121 | Implantation of cardiac resynchronization therapy systems in the CARE-HF trial: procedural success rate and safety. Europace, 2007, 9, 516-522. | 0.7 | 160 |
| 122 | The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. European Heart Journal, 2006, 28, 42-51. | 1.0 | 159 |
| 123 | A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study). Heart, 2009, 95, 924-930. | 1.2 | 159 |
| 124 | The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. European Heart Journal, 2010, 31, 832-841. | 1.0 | 159 |
| 125 | The Predictive Value of Short-Term Changes in Hemoglobin Concentration in Patients Presenting With Acute Decompensated Heart Failure. Journal of the American College of Cardiology, 2013, 61, 1973-1981. | 1.2 | 159 |
| 126 | Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Lancet, The, 2019, 394, 1254-1263. | 6.3 | 159 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. American Heart Journal, 1994, 127, 607-612. | 1.2 | 157 |
| 128 | Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. International Journal of Cardiology, 2018, 258, 185-191. | 0.8 | 157 |
| 129 | Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure. European Heart Journal, 2010, 31, 2280-2290. | 1.0 | 155 |
| 130 | Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. European Heart Journal, 2005, 26, 2259-2268. | 1.0 | 154 |
| 131 | A Meta-Analysis Reporting Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients Without Heart Failure. Journal of the American College of Cardiology, 2013, 61, 131-142. | 1.2 | 154 |
| 132 | Family planning in sub-Saharan Africa: progress or stagnation?TP. Bulletin of the World Health Organization, 2011, 89, 137-143. | 1.5 | 151 |
| 133 | IVC Diameter in Patients With Chronic Heart Failure. JACC: Cardiovascular Imaging, 2013, 6, 16-28. | 2.3 | 151 |
| 134 | A systems <scp>BIOlogy</scp> Study to <scp>TAilored</scp> Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of <scp>BIOSTATâ€CHF</scp> . European Journal of Heart Failure, 2016, 18, 716-726. | 2.9 | 149 |
| 135 | Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. European Journal of Heart Failure, 2001, 3, 381-387. | 2.9 | 148 |
| 136 | Diastolic heart failure: neglected or misdiagnosed?. Journal of the American College of Cardiology, 2002, 39, 138-141. | 1.2 | 147 |
| 137 | Predictors and treatment response with cardiac resynchronization therapy in patients with heart failure characterized by dyssynchrony: a pre-defined analysis from the CARE-HF trial. European Heart Journal, 2007, 28, 1827-1834. | 1.0 | 147 |
| 138 | The Obesity Paradox in Type 2 Diabetes Mellitus: Relationship of Body Mass Index to Prognosis. Annals of Internal Medicine, 2015, 162, 610-618. | 2.0 | 147 |
| 139 | Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. European Heart Journal, 2007, 28, 1592-1597. | 1.0 | 144 |
| 140 | Levosimendan vs. dobutamine: outcomes for acute heart failure patients on βâ€blockers in SURVIVEâ€. European Journal of Heart Failure, 2009, 11, 304-311. | 2.9 | 144 |
| 141 | Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). European Heart Journal, 2012, 33, 2290-2296. | 1.0 | 144 |
| 142 | Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. American Heart Journal, 2011, 162, 900-906. | 1.2 | 143 |
| 143 | Enhanced basal nitric oxide production in heart failure: another failed counter-regulatory vasodilator mechanism?. Lancet, The, 1994, 344, 371-373. | 6.3 | 140 |
| 144 | Red cell distribution width: an inexpensive and powerful prognostic marker in heart failure. European Journal of Heart Failure, 2009, 11, 1155-1162. | 2.9 | 140 |

| # | Article | IF | CITATIONS |
|-----|---|------|-----------|
| 145 | Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. International Journal of Cardiology, 2018, 271, 132-139. | 0.8 | 140 |
| 146 | The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet, The, 2019, 393, 2155-2167. | 6.3 | 140 |
| 147 | Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure, 1999, 1, 211-217. | 2.9 | 139 |
| 148 | Determinants and Consequences of Renal Function Variations With Aldosterone Blocker Therapy in Heart Failure Patients After Myocardial Infarction. Circulation, 2012, 125, 271-279. | 1.6 | 136 |
| 149 | Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart, 2007, 93, 968-973. | 1.2 | 135 |
| 150 | Prevalence of, Associations With, and Prognostic Value of Tricuspid Annular Plane Systolic Excursion (TAPSE) Among Out-Patients Referred for the Evaluation of Heart Failure. Journal of Cardiac Failure, 2012, 18, 216-225. | 0.7 | 135 |
| 151 | Unmet Need for Contraception: Issues and Challenges. Studies in Family Planning, 2014, 45, 105-122. | 1.0 | 135 |
| 152 | Do unintended pregnancies carried to term lead to adverse outcomes for mother and child? An assessment in five developing countries. Population Studies, 2003, 57, 77-93. | 1.1 | 134 |
| 153 | Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes. Circulation: Heart Failure, 2010, 3, 314-325. | 1.6 | 134 |
| 154 | The effects of aetiology on outcome in patients treated with cardiac resynchronization therapy in the CARE-HF trial. European Heart Journal, 2008, 30, 782-788. | 1.0 | 132 |
| 155 | Should we screen for asymptomatic left ventricular dysfunction to prevent heart failure?. European Heart Journal, 1998, 19, 842-846. | 1.0 | 131 |
| 156 | A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. European Heart Journal, 2008, 29, 816-824. | 1.0 | 131 |
| 157 | e-Health: a position statement of the European Society of Cardiology. European Heart Journal, 2016, 37, 63-66. | 1.0 | 131 |
| 158 | The prevalence of heart failure and asymptomatic left ventricular systolic dysfunction in a typical regional pacemaker population. European Heart Journal, 2003, 24, 1143-1152. | 1.0 | 130 |
| 159 | Targeting myocardial substrate metabolism in heart failure: potential for new therapies. European Journal of Heart Failure, 2012, 14, 120-129. | 2.9 | 130 |
| 160 | Predicting hospitalization due to worsening heart failure using daily weight measurement: analysis of the Transâ€European Networkâ€Homeâ€Care Management System (TENâ€HMS) study. European Journal of Hea Failure, 2009, 11, 420-427. | t2.9 | 129 |
| 161 | Prevalence and predictors of anxiety and depression in a sample of chronic heart failure patients with left ventricular systolic dysfunction. European Journal of Heart Failure, 2005, 7, 803-808. | 2.9 | 128 |
| 162 | The national heart failure audit for England and Wales 2008-2009. Heart, 2011, 97, 876-886. | 1.2 | 128 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey. European Heart Journal, 2008, 29, 1618-1624. | 1.0 | 127 |
| 164 | Micronutrient Deficiencies. Journal of the American College of Cardiology, 2009, 54, 1660-1673. | 1.2 | 127 |
| 165 | Is aspirin safe for patients with heart failure?. Heart, 1995, 74, 215-219. | 1.2 | 126 |
| 166 | Is the prognosis of heart failure improving?. Journal of the American College of Cardiology, 2000, 36, 2284-2286. | 1.2 | 126 |
| 167 | Anemia, Renal Dysfunction, and Their Interaction in Patients With Chronic Heart Failure. American Journal of Cardiology, 2006, 98, 391-398. | 0.7 | 125 |
| 168 | Effects of the Adenosine A1 Receptor Antagonist Rolofylline on Renal Function in Patients With Acute Heart Failure and Renal Dysfunction. Journal of the American College of Cardiology, 2011, 57, 1899-1907. | 1.2 | 125 |
| 169 | Heart failure with preserved ejection fraction: uncertainties and dilemmas. European Journal of Heart Failure, 2015, 17, 665-671. | 2.9 | 124 |
| 170 | Treatments targeting inotropy. European Heart Journal, 2019, 40, 3626-3644. | 1.0 | 123 |
| 171 | Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. European Heart Journal, 2005, 26, 2681-2688. | 1.0 | 121 |
| 172 | Longâ€ŧerm mortality with cardiac resynchronization therapy in the Cardiac Resynchronizationâ€Heart Failure (CAREâ€HF) trial. European Journal of Heart Failure, 2012, 14, 628-634. | 2.9 | 121 |
| 173 | One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial. JAMA Cardiology, 2018, 3, 968. | 3.0 | 121 |
| 174 | Predictors of fatal and nonâ€fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein Aâ€1, highâ€sensitivity Câ€reactive peptide and Nâ€terminal pro Bâ€type natriuretic peptide. European Journal of Heart Failure, 2009, 11, 281-291. | 2.9 | 120 |
| 175 | Is Heart Rate Important for Patients With Heart Failure in Atrial Fibrillation?. JACC: Heart Failure, 2014, 2, 213-220. | 1.9 | 120 |
| 176 | Sexual abstinence, contraception, and condom use by young African women: a secondary analysis of survey data. Lancet, The, 2006, 368, 1788-1793. | 6.3 | 119 |
| 177 | Cardiac resynchronisation for patients with heart failure due to left ventricular systolic dysfunction - a systematic review and meta-analysis. European Journal of Heart Failure, 2006, 8, 433-440. | 2.9 | 119 |
| 178 | Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Failure Reviews, 2013, 18, 123-134. | 1.7 | 118 |
| 179 | Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease. Circulation, 2019, 140, 542-552. | 1.6 | 118 |
| 180 | Prevalence and Outcomes of Anemia and Hematinic Deficiencies in Patients With Chronic Heart Failure. JAMA Cardiology, 2016, 1, 539. | 3.0 | 117 |

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. Circulation: Heart Failure, 2018, 11, e004962. | 1.6 | 117 |
| 182 | Influence of concomitant disease on patterns of hospitalization in patients with heart failure discharged from Scottish hospitals in 1995. European Heart Journal, 1998, 19, 1063-1069. | 1.0 | 116 |
| 183 | Systematic review of the management of atrial fibrillation in patients with heart failure. European Heart Journal, 2000, 21, 614-632. | 1.0 | 116 |
| 184 | The reproducibility and sensitivity of the 6-min walk test in elderly patients with chronic heart failure. European Heart Journal, 2005, 26, 1742-1751. | 1.0 | 115 |
| 185 | The PROTECT inâ€hospital risk model: 7â€day outcome in patients hospitalized with acute heart failure and renal dysfunction. European Journal of Heart Failure, 2012, 14, 605-612. | 2.9 | 115 |
| 186 | Remote monitoring after recent hospital discharge in patients with heart failure: a systematic review and network meta-analysis. Heart, 2013, 99, 1717-1726. | 1.2 | 114 |
| 187 | Recommendations for exercise testing in chronic heart faliure patients. European Heart Journal, 2001, 22, 37-45. | 1.0 | 113 |
| 188 | Decongestion in acute heart failure. European Journal of Heart Failure, 2014, 16, 471-482. | 2.9 | 113 |
| 189 | Chronic heart failure, chronotropic incompetence, and the effects of blockade. Heart, 2005, 92, 481-486. | 1.2 | 112 |
| 190 | Prognostic value of systolic mitral annular velocity measured with Doppler tissue imaging in patients with chronic heart failure caused by left ventricular systolic dysfunction. Heart, 2005, 92, 775-779. | 1.2 | 112 |
| 191 | The timing of development and subsequent clinical course of heart failure after a myocardial infarction. European Heart Journal, 2008, 29, 859-870. | 1.0 | 112 |
| 192 | Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. European Journal of Heart Failure, 2012, 14, 268-277. | 2.9 | 110 |
| 193 | Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. Lancet, The, 1998, 351, 1657-1658. | 6.3 | 109 |
| 194 | Are hematinic deficiencies the cause of anemia in chronic heart failure?. American Heart Journal, 2004, 147, 924-930. | 1.2 | 109 |
| 195 | Left atrial function measured by cardiac magnetic resonance imaging in patients with heart failure: clinical associations and prognostic value. European Heart Journal, 2015, 36, 733-742. | 1.0 | 109 |
| 196 | The standard electrocardiogram as a screening test for hypertrophic cardiomyopathy. American Journal of Cardiology, 1995, 76, 689-694. | 0.7 | 108 |
| 197 | Predictors of Postdischarge Outcomes From Information Acquired Shortly After Admission for Acute Heart Failure. Circulation: Heart Failure, 2014, 7, 76-87. | 1.6 | 107 |
| 198 | CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients—who is doing what to whom and how?. European Journal of Heart Failure, 2018, 20, 1039-1051. | 2.9 | 107 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Temporal Trends and Patterns in Mortality After Incident Heart Failure. JAMA Cardiology, 2019, 4, 1102. | 3.0 | 107 |
| 200 | Coenzyme Q10, Rosuvastatin, and Clinical Outcomes in Heart Failure. Journal of the American College of Cardiology, 2010, 56, 1196-1204. | 1.2 | 105 |
| 201 | Beta-blocking agents in heart failure Should they be used and how?. European Heart Journal, 1996, 17, 1629-1639. | 1.0 | 104 |
| 202 | Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. The Lancet Global Health, 2020, 8, e411-e422. | 2.9 | 104 |
| 203 | Management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I. European Heart Journal, 2007, 28, 1310-1318. | 1.0 | 103 |
| 204 | Successes and failures of current treatment of heart failure. Lancet, The, 1998, 352, SI19-SI28. | 6.3 | 102 |
| 205 | Prognostic burden of heart failure recorded in primary care, acute hospital admissions, or both: a populationâ€based linked electronic health record cohort study in 2.1 million people. European Journal of Heart Failure, 2017, 19, 1119-1127. | 2.9 | 101 |
| 206 | Exploring symptoms in chronic heart failure. European Journal of Heart Failure, 2005, 7, 699-703. | 2.9 | 100 |
| 207 | Prevalence, pattern and clinical relevance of ultrasound indices of congestion in outpatients with heart failure. European Journal of Heart Failure, 2019, 21, 904-916. | 2.9 | 100 |
| 208 | Etiology and response to drug treatment in heart failure. Journal of the American College of Cardiology, 1998, 32, 1167-1172. | 1.2 | 99 |
| 209 | Effect of Rosuvastatin on Repeat Heart Failure Hospitalizations. JACC: Heart Failure, 2014, 2, 289-297. | 1.9 | 99 |
| 210 | Atrial Fibrillation and Heart Failure in Cardiology Practice: Reciprocal Impact and Combined Management From the Perspective of Atrial Fibrillation. Journal of the American College of Cardiology, 2009, 53, 1690-1698. | 1.2 | 98 |
| 211 | The Warfarin and Antiplatelet Therapy in Heart Failure Trial (WATCH): rationale, design, and baseline patient characteristics. Journal of Cardiac Failure, 2004, 10, 101-112. | 0.7 | 97 |
| 212 | Effects of cardiac resynchronization therapy on long-term quality of life: An analysis from the CArdiac Resynchronisation-Heart Failure (CARE-HF) study. American Heart Journal, 2009, 157, 457-466. | 1.2 | 96 |
| 213 | The evidence for beta Âblockers in heart failure. BMJ: British Medical Journal, 1999, 318, 824-825. | 2.4 | 95 |
| 214 | Effect of age and sex on efficacy and tolerability of \hat{I}^2 blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. BMJ, The, 2016, 353, i1855. | 3.0 | 95 |
| 215 | Update of REACH-1 and MERIT-HF clinical trials in heart failure. European Journal of Heart Failure, 1999, 1, 197-200. | 2.9 | 94 |
| 216 | Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure. American Heart Journal, 2007, 153, 1048-1055. | 1.2 | 93 |

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 217 | Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. European Journal of Heart Failure, 2018, 20, 888-895. | 2.9 | 93 |
| 218 | Effect of Captopril, an angiotensin-converting enzyme inhibitor, in patients with angina pectoris and heart failure. Journal of the American College of Cardiology, 1991, 17, 733-739. | 1.2 | 92 |
| 219 | Effects of increased inspired oxygen concentrations on exercise performance in chronic heart failure. Lancet, The, 1992, 339, 850-853. | 6.3 | 92 |
| 220 | Sex―and ageâ€based differences in the natural history and outcome of dilated cardiomyopathy. European Journal of Heart Failure, 2018, 20, 1392-1400. | 2.9 | 92 |
| 221 | Prevalence of ECG abnormalities in an international survey of patients with suspected or confirmed heart failure at death or discharge. European Journal of Heart Failure, 2007, 9, 491-501. | 2.9 | 91 |
| 222 | The European Cardiac Resynchronization Therapy Survey: comparison of outcomes between de novo cardiac resynchronization therapy implantations and upgrades. European Journal of Heart Failure, 2011, 13, 974-983. | 2.9 | 91 |
| 223 | What is the ideal study design for evaluation of treatment for heart failure?: Insights from trials assessing the effect of ACE inhibitors on exercise capacity. European Heart Journal, 1996, 17, 120-134. | 1.0 | 89 |
| 224 | Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT. European Journal of Heart Failure, 2000, 2, 209-212. | 2.9 | 89 |
| 225 | Short-term haemodynamic effects of BQ-123, a selective endothelin ETA-receptor antagonist, in chronic heart failure. Lancet, The, 1998, 352, 201-202. | 6.3 | 88 |
| 226 | Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2016, 18, 328-336. | 2.9 | 88 |
| 227 | The European CRT Survey: 1 year (9–15 months) followâ€up results. European Journal of Heart Failure, 2012, 14, 61-73. | 2.9 | 87 |
| 228 | Ultrasound imaging of congestion in heart failure: examinations beyond the heart. European Journal of Heart Failure, 2021, 23, 703-712. | 2.9 | 87 |
| 229 | The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation. European Heart Journal, 2006, 27, 2353-2361. | 1.0 | 85 |
| 230 | Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. European Journal of Heart Failure, 2007, 9, 901-909. | 2.9 | 85 |
| 231 | Increased blood lactate is prevalent and identifies poor prognosis in patients with acute heart failure without overt peripheral hypoperfusion. European Journal of Heart Failure, 2018, 20, 1011-1018. | 2.9 | 85 |
| 232 | Waistâ€ŧoâ€hip ratio and mortality in heart failure. European Journal of Heart Failure, 2018, 20, 1269-1277. | 2.9 | 85 |
| 233 | Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. European Heart Journal, 2011, 32, 1519-1534. | 1.0 | 84 |
| 234 | Selenium and outcome in heart failure. European Journal of Heart Failure, 2020, 22, 1415-1423. | 2.9 | 84 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 235 | Short-term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. European Journal of Heart Failure, 2011, 13, 1006-1012. | 2.9 | 82 |
| 236 | Impact of Serial Troponin Release on Outcomes in Patients With Acute Heart Failure. Circulation: Heart Failure, 2011, 4, 724-732. | 1.6 | 82 |
| 237 | Charting a Roadmap for Heart Failure Biomarker Studies. JACC: Heart Failure, 2014, 2, 477-488. | 1.9 | 81 |
| 238 | Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial. Nephrology Dialysis Transplantation, 2016, 31, gfv346. | 0.4 | 81 |
| 239 | The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individualâ€patient data metaâ€analysis. European Journal of Heart Failure, 2018, 20, 780-791. | 2.9 | 81 |
| 240 | Demographic Data Collection in Less Developed Countries 1946–1996. Population Studies, 1996, 50, 433-450. | 1.1 | 80 |
| 241 | Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction. American Journal of Medicine, 2005, 118, 752-758. | 0.6 | 80 |
| 242 | Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure. Circulation: Heart Failure, 2016, 9, . | 1.6 | 80 |
| 243 | Combined use of lung ultrasound, B-type natriuretic peptide, and echocardiography for outcome prediction in patients with acute HFrEF and HFpEF. Clinical Research in Cardiology, 2018, 107, 586-596. | 1.5 | 79 |
| 244 | Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from <scp>BIOSTATâ€CHF</scp> . European Journal of Heart Failure, 2017, 19, 1284-1293. | 2.9 | 79 |
| 245 | New generation 3-dimensional echocardiography for left ventricular volumetric and functional measurements: Comparison with cardiac magnetic resonance. European Journal of Echocardiography, 2006, 7, 365-372. | 2.3 | 78 |
| 246 | A personalised mobile-based home monitoring system for heart failure: The SUPPORT-HF Study. International Journal of Medical Informatics, 2015, 84, 743-753. | 1.6 | 78 |
| 247 | Biomarker Profiles of AcuteÂHeartÂFailureÂPatients With aÂMid-Range EjectionÂFraction. JACC: Heart Failure, 2017, 5, 507-517. | 1.9 | 78 |
| 248 | The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. European Heart Journal, 2021, 42, 1254-1269. | 1.0 | 78 |
| 249 | World Population Growth; Past, Present and Future. Environmental and Resource Economics, 2013, 55, 543-554. | 1.5 | 77 |
| 250 | A novel method to predict the proportional risk of sudden cardiac death in heart failure: Derivation of the Seattle Proportional Risk Model. Heart Rhythm, 2015, 12, 2069-2077. | 0.3 | 77 |
| 251 | The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart â€~OMics' in AGEing (HOMAGE) randomized clinical trial. European Heart Journal, 2021, 42, 684-696. | 1.0 | 77 |
| 252 | Acute Saline Infusion Reduces Alveolar-Capillary Membrane Conductance and Increases Airflow Obstruction in Patients With Left Ventricular Dysfunction. Circulation, 1999, 99, 1190-1196. | 1.6 | 76 |

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 253 | Toleration of High Doses of Angiotensin-Converting Enzyme Inhibitors in Patients With Chronic Heart Failure. Archives of Internal Medicine, 2001, 161, 165. | 4.3 | 76 |
| 254 | Clinical events leading to the progression of heart failure: insights from a national database of hospital discharges. European Heart Journal, 2001, 22, 153-164. | 1.0 | 76 |
| 255 | Color tissue Doppler-derived long-axis left ventricular function in heart failure with preserved global systolic function. American Journal of Cardiology, 2002, 90, 1174-1177. | 0.7 | 76 |
| 256 | NHS heart failure survey: a survey of acute heart failure admissions in England, Wales and Northern Ireland. Heart, 2008, 94, 172-177. | 1.2 | 76 |
| 257 | Relationship between right ventricular volumes measured by cardiac magnetic resonance imaging and prognosis in patients with chronic heart failure. European Journal of Heart Failure, 2011, 13, 52-60. | 2.9 | 76 |
| 258 | Clinical trials with endothelin receptor antagonists: What went wrong and where can we improve?. Life Sciences, 2012, 91, 528-539. | 2.0 | 76 |
| 259 | Prognostic value of psychosocial factors for first and recurrent hospitalizations and mortality in heart failure patients: insights from the OPERAâ€HF study. European Journal of Heart Failure, 2018, 20, 689-696. | 2.9 | 76 |
| 260 | Muscle wasting as an independent predictor of survival in patients with chronic heart failure. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 1242-1249. | 2.9 | 76 |
| 261 | Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Coâ€morbidities Aggravating Heart Failure (SICAâ€HF). Journal of Cachexia, Sarcopenia and Muscle, 2010, 1, 187-194. | 2.9 | 75 |
| 262 | Effect of oral digoxin in highâ€risk heart failure patients: a preâ€specified subgroup analysis of the DIG trial. European Journal of Heart Failure, 2013, 15, 551-559. | 2.9 | 75 |
| 263 | Cardiac Dysfunction, Congestion and Loop Diuretics: their Relationship to Prognosis in Heart Failure. Cardiovascular Drugs and Therapy, 2016, 30, 599-609. | 1.3 | 75 |
| 264 | Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure—COMET. American Heart Journal, 2005, 149, 370-376. | 1.2 | 74 |
| 265 | Heart rate achieved or betaâ€blocker dose in patients with chronic heart failure: which is the better target?. European Journal of Heart Failure, 2012, 14, 737-747. | 2.9 | 74 |
| 266 | Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis. Heart Failure Reviews, 2012, 17, 133-149. | 1.7 | 74 |
| 267 | Interplay Between Right Ventricular Function and Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2013, 61, 2153-2160. | 1.2 | 74 |
| 268 | Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure. Heart, 2017, 103, 407-413. | 1.2 | 74 |
| 269 | Prognostic value of the 6 min walk test and self-perceived symptom severity in older patients with chronic heart failure. European Heart Journal, 2006, 28, 560-568. | 1.0 | 73 |
| 270 | Fitness to fly for passengers with cardiovascular disease. Heart, 2010, 96, ii1-ii16. | 1.2 | 73 |

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 271 | Rationale and design of a randomized, doubleatening, eventatedriven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the <scp>COMMANDER HF</scp> trial. European Journal of Heart | 2.9 | 73 |
| 272 | Effect of age and sex on left atrial morphology and function. European Journal of Echocardiography, 2003, 4, 36-42. | 2.3 | 73 |
| 273 | Criteria for Iron Deficiency in PatientsÂWith HeartÂFailure. Journal of the American College of Cardiology, 2022, 79, 341-351. | 1.2 | 73 |
| 274 | Angiotensin II levels, hemodynamics, and sympathoadrenal function after low-dose captopril in heart failure. American Journal of Medicine, 1984, 77, 880-886. | 0.6 | 72 |
| 275 | The heart failure revascularisation trial (HEART): rationale, design and methodology. European Journal of Heart Failure, 2003, 5, 295-303. | 2.9 | 72 |
| 276 | Baseline characteristics of patients recruited into the CARE-HF study. European Journal of Heart Failure, 2005, 7, 205-214. | 2.9 | 72 |
| 277 | Long-term effect of cardiac resynchronisation in patients reporting mild symptoms of heart failure: a report from the CARE-HF study. Heart, 2008, 94, 278-283. | 1.2 | 72 |
| 278 | Body mass indices and outcome in patients with chronic heart failure. European Journal of Heart Failure, 2011, 13, 207-213. | 2.9 | 72 |
| 279 | Who Meets the Contraceptive Needs of Young Women in Sub-Saharan Africa?. Journal of Adolescent Health, 2018, 62, 273-280. | 1.2 | 72 |
| 280 | Enhanced External Counterpulsation in the Treatment of Chronic Refractory Angina: A Longâ€ŧerm Followâ€up Outcome from the International Enhanced External Counterpulsation Patient Registry. Clinical Cardiology, 2008, 31, 159-164. | 0.7 | 71 |
| 281 | International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better shortâ€ŧerm outcomes in patients enrolled in Eastern Europe and Russia in the <scp>PROTECT</scp> trial. European Journal of Heart Failure, 2014, 16, 614-624. | 2.9 | 71 |
| 282 | Structured telephone support or non-invasive telemonitoring for patients with heart failure. Heart, 2017, 103, 255-257. | 1.2 | 71 |
| 283 | Immunomodulatory interventions in myocardial infarction and heart failure: a systematic review of clinical trials and meta-analysis of IL-1 inhibition. Cardiovascular Research, 2018, 114, 1445-1461. | 1.8 | 71 |
| 284 | Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rateâ€lowering properties. European Journal of Heart Failure, 2014, 16, 76-85. | 2.9 | 70 |
| 285 | Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the <scp>PROTECT</scp> study. European Journal of Heart Failure, 2016, 18, 830-839. | 2.9 | 70 |
| 286 | Sudden death in heart failure: vascular or electrical?. European Journal of Heart Failure, 1999, 1, 41-45. | 2.9 | 69 |
| 287 | Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. European Journal of Heart Failure, 2002, 4, 321-329. | 2.9 | 69 |
| 288 | Prognostic importance of plasma NTâ€pro BNP in chronic heart failure in patients treated with a βâ€blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial. European Journal of Heart Failure, 2007, 9, 795-801. | 2.9 | 69 |

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 289 | Optimizing clinical use of biomarkers in highâ€risk acute heart failure patients. European Journal of Heart Failure, 2016, 18, 269-280. | 2.9 | 69 |
| 290 | A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. European Heart Journal, 2019, 40, 3593-3602. | 1.0 | 69 |
| 291 | Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (<scp>HFA</scp>), European Society of Cardiology (<scp>ESC</scp>). European Journal of Heart Failure, 2021, 23, 1610-1632. | 2.9 | 69 |
| 292 | Association with outcomes and response to treatment of trimethylamine Nâ€oxide in heart failure: results from BIOSTATâ€CHF. European Journal of Heart Failure, 2019, 21, 877-886. | 2.9 | 68 |
| 293 | Tezosentan in patients with acute heart failure: Design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). American Heart Journal, 2005, 150, 46-53. | 1.2 | 67 |
| 294 | Trends in Protective Behaviour among Single vs. Married Young Women in Sub-Saharan Africa: The Big Picture. Reproductive Health Matters, 2006, 14, 17-22. | 1.3 | 66 |
| 295 | A Comparison of the Effects of Carvedilol and Metoprolol on Well-Being, Morbidity, and Mortality (the "Patient Journeyâ€) in Patients With Heart Failure. Journal of the American College of Cardiology, 2006, 47, 1603-1611. | 1.2 | 66 |
| 296 | The effect of altering heart rate on ventricular function in patients with heart failure treated with β-blockers. American Heart Journal, 2006, 152, 713.e9-713.e13. | 1.2 | 66 |
| 297 | Important Differences in Mode of Death Between Men and Women With Heart Failure Who Would Qualify for a Primary Prevention Implantable Cardioverter-Defibrillator. Circulation, 2012, 126, 2402-2407. | 1.6 | 66 |
| 298 | COVID-19 and its cardiovascular effects: a systematic review of prevalence studies. The Cochrane Library, 2022, 2022, CD013879. | 1.5 | 66 |
| 299 | Prevalence and incidence of arrhythmias and sudden death in heart failure. Heart Failure Reviews, 2002, 7, 229-242. | 1.7 | 65 |
| 300 | Causes and treatment of oedema in patients with heart failure. Nature Reviews Cardiology, 2013, 10, 156-170. | 6.1 | 65 |
| 301 | Acute Heart Failure in the Elderly: Differences in Clinical Characteristics, Outcomes, and Prognostic Factors in the VERITAS Study. Journal of Cardiac Failure, 2015, 21, 179-188. | 0.7 | 65 |
| 302 | Reasons for unmet need for family planning, with attention to the measurement of fertility preferences: protocol for a multi-site cohort study. Reproductive Health, 2017, 14, 23. | 1.2 | 65 |
| 303 | Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 2109-2117. | 1.0 | 65 |
| 304 | Implementing the Integration of Component Services for Reproductive Health. Studies in Family Planning, 2000, 31, 151-162. | 1.0 | 64 |
| 305 | Reproductive Consequences of Contraceptive Failure in 19 Developing Countries. Obstetrics and Gynecology, 2004, 104, 314-320. | 1.2 | 64 |
| 306 | What proportion of patients with chronic heart failure are eligible for sacubitril–valsartan?. European Journal of Heart Failure, 2017, 19, 768-778. | 2.9 | 64 |

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 307 | Bioâ€adrenomedullin as a marker of congestion in patients with newâ€onset and worsening heart failure. European Journal of Heart Failure, 2019, 21, 732-743. | 2.9 | 64 |
| 308 | A Comparison of Patient and Physician-Rated New York Heart Association Class in a Community-Based Heart Failure Clinic. Journal of Cardiac Failure, 2008, 14, 379-387. | 0.7 | 63 |
| 309 | Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. Circulation: Heart Failure, 2019, 12, e005897. | 1.6 | 63 |
| 310 | Caring for people with heart failure and many other medical problems through and beyond the <scp>COVID</scp> â€19 pandemic: the advantages of universal access to home telemonitoring. European Journal of Heart Failure, 2020, 22, 995-998. | 2.9 | 63 |
| 311 | Epidemiology and management of heart failure and left ventricular systolic dysfunction in the aftermath of a myocardial infarction. Heart, 2005, 91, ii7-ii13. | 1.2 | 62 |
| 312 | Carvedilol Protects Better Against Vascular Events Than Metoprolol in Heart Failure. Journal of the American College of Cardiology, 2007, 49, 963-971. | 1.2 | 62 |
| 313 | Iron deficiency in patients with heart failure with preserved ejection fraction and its association with reduced exercise capacity, muscle strength and quality of life. Clinical Research in Cardiology, 2019, 108, 203-211. | 1.5 | 62 |
| 314 | Body mass index and all-cause mortality in heart failure patients with normal and reduced ventricular ejection fraction: a dose–response meta-analysis. Clinical Research in Cardiology, 2019, 108, 119-132. | 1.5 | 62 |
| 315 | Do discharge codes underestimate hospitalisation due to heart failure? Validation study of hospital discharge coding for heart failure. European Journal of Heart Failure, 2005, 7, 792-797. | 2.9 | 61 |
| 316 | Left ventricular morphology, global and longitudinal function in normal older individuals: A cardiac magnetic resonance study. International Journal of Cardiology, 2006, 108, 76-83. | 0.8 | 61 |
| 317 | International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: Data from the EuroHeart Failure Survey. European Journal of Heart Failure, 2007, 9, 292-299. | 2.9 | 61 |
| 318 | Relationship between plasma concentrations of Nâ€terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEPâ€CHF study. European Journal of Heart Failure, 2012, 14, 487-494. | 2.9 | 61 |
| 319 | Iron Status and Survival in Diabetic Patients With Coronary Artery Disease. Diabetes Care, 2013, 36, 4147-4156. | 4.3 | 61 |
| 320 | Has the survival of the heart failure population changed? lessons from trials. American Journal of Cardiology, 1999, 83, 112-119. | 0.7 | 60 |
| 321 | Adherence and perception of medication in patients with chronic heart failure during a five-year randomised trial. Patient Education and Counseling, 2006, 61, 348-353. | 1.0 | 60 |
| 322 | Clinical trials update from the American College of Cardiology meeting 2010: DOSE, ASPIRE, CONNECT, STICH, STOP-AF, CABANA, RACE II, EVEREST II, ACCORD, and NAVIGATOR. European Journal of Heart Failure, 2010, 12, 623-629. | 2.9 | 60 |
| 323 | Renal Function Trajectories and Clinical Outcomes in Acute Heart Failure. Circulation: Heart Failure, 2014, 7, 59-67. | 1.6 | 60 |
| 324 | Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60â€day outcomes in the PROTECT pilot study. European Journal of Heart Failure, 2010, 12, 499-507. | 2.9 | 59 |

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 325 | Anticoagulant and antiplatelet therapy in heart failure. Current Opinion in Cardiology, 1997, 12, 276-287. | 0.8 | 58 |
| 326 | The LIDO, HOPE, MOXCON and WASH studies. European Journal of Heart Failure, 1999, 1, 425-431. | 2.9 | 58 |
| 327 | Pulmonary artery pressure measurement during exercise testing in patients with suspected pulmonary hypertension. European Respiratory Journal, 2000, 16, 282. | 3.1 | 58 |
| 328 | Recall of lifestyle advice in patients recently hospitalised with heart failure: A EuroHeart Failure Survey analysis. European Journal of Heart Failure, 2007, 9, 1095-1103. | 2.9 | 58 |
| 329 | Epidemiology, Associated Factors, and Prognostic Outcomes of Renal Artery Stenosis in Chronic Heart Failure Assessed by Magnetic Resonance Angiography. American Journal of Cardiology, 2007, 100, 273-279. | 0.7 | 58 |
| 330 | Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2009, 53, 608-611. | 1.2 | 58 |
| 331 | Prognostic Significance of Creatinine Increases During an Acute Heart Failure Admission in Patients With and Without Residual Congestion. Circulation: Heart Failure, 2018, 11, e004644. | 1.6 | 58 |
| 332 | High-sensitivity C-reactive protein in chronic heart failure: patient characteristics, phenotypes, and mode of death. Cardiovascular Research, 2020, 116, 91-100. | 1.8 | 58 |
| 333 | Global longitudinal strain in patients with suspected heart failure and a normal ejection fraction: does it improve diagnosis and risk stratification?. International Journal of Cardiovascular Imaging, 2014, 30, 69-79. | 0.7 | 57 |
| 334 | Interventions to Improve Postpartum Family Planning in Low―and Middleâ€Income Countries: Program Implications and Research Priorities. Studies in Family Planning, 2015, 46, 423-441. | 1.0 | 57 |
| 335 | Potassium and the use of renin–angiotensin–aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT HF. European Journal of Heart Failure, 2018, 20, 923-930. | 2.9 | 57 |
| 336 | Is aspirin ″the weakest link―in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease. Progress in Cardiovascular Diseases, 2002, 44, 275-292. | 1.6 | 56 |
| 337 | Glycated Hemoglobin, Prediabetes, and the Links to Cardiovascular Disease: Data From UK Biobank. Diabetes Care, 2020, 43, 440-445. | 4.3 | 56 |
| 338 | Prognostic value of the VE/VCO2 slope calculated from different time intervals in patients with suspected heart failure. International Journal of Cardiology, 2007, 118, 350-355. | 0.8 | 55 |
| 339 | Lack of Diastolic Reserve in Patients With Heart Failure and Normal Ejection Fraction. Circulation: Heart Failure, 2010, 3, 35-43. | 1.6 | 55 |
| 340 | Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. International Journal of Cardiology, 2018, 253, 84-90. | 0.8 | 55 |
| 341 | The struggle towards a Universal Definition of Heart Failure—how to proceed?. European Heart Journal, 2021, 42, 2331-2343. | 1.0 | 55 |
| 342 | The Carvedilol Hibernation Reversible Ischaemia Trial; Marker of Success (CHRISTMAS). European Journal of Heart Failure, 1999, 1, 191-196. | 2.9 | 54 |

| # | Article | IF | CITATIONS |
|-----|---|------|-----------|
| 343 | DETERMINANTS OF CONTRACEPTIVE DISCONTINUATION IN SIX DEVELOPING COUNTRIES. Journal of Biosocial Science, 1999, 31, 343-360. | 0.5 | 54 |
| 344 | Exercise capacity and cardiac function assessed by tissue Doppler imaging in chronic heart failure. Heart, 2004, 90, 1144-1150. | 1.2 | 54 |
| 345 | The prognostic value of repeated measurement of Nâ€terminal proâ€Bâ€type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction. European Journal of Heart Failure, 2009, 11, 367-377. | 2.9 | 54 |
| 346 | Digoxin Reduces 30-day All-cause Hospital Admission in Older Patients with Chronic Systolic Heart Failure. American Journal of Medicine, 2013, 126, 701-708. | 0.6 | 54 |
| 347 | EndothelinBreceptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction. Journal of the American College of Cardiology, 1999, 33, 932-938. | 1.2 | 53 |
| 348 | Selfâ€rated health and mortality in patients with chronic heart failure. European Journal of Heart Failure, 2009, 11, 518-524. | 2.9 | 53 |
| 349 | Measurement of breathlessness in clinical trials in patients with chronic heart failure: the need for a standardized approach: a systematic review. European Journal of Heart Failure, 2010, 12, 137-147. | 2.9 | 53 |
| 350 | Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. International Journal of Cardiology, 2016, 224, 231-239. | 0.8 | 53 |
| 351 | The effects of shortâ€ŧerm omission of daily medication on the pathophysiology of heart failure. European Journal of Heart Failure, 2017, 19, 643-649. | 2.9 | 53 |
| 352 | A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure. European Journal of Heart Failure, 2017, 19, 1310-1320. | 2.9 | 53 |
| 353 | The key lesson of family planning programmes for HIV/AIDS control. Aids, 2006, 20, 1-3. | 1.0 | 52 |
| 354 | Prognosis in Heart Failure with a Normal Ejection Fraction. New England Journal of Medicine, 2007, 357, 829-830. | 13.9 | 52 |
| 355 | The Safety of Amiodarone in Patients With Heart Failure. Journal of Cardiac Failure, 2007, 13, 340-345. | 0.7 | 52 |
| 356 | International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORTâ€HF): rationale for and design of a global registry. European Journal of Heart Failure, 2015, 17, 527-533. | 2.9 | 52 |
| 357 | Substantial decline in hospital admissions for heart failure accompanied by increased community mortality during COVID-19 pandemic. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 378-387. | 1.8 | 52 |
| 358 | Clinical determinants of poor six-minute walk test performance in patients with left ventricular systolic dysfunction and no major structural heart disease. European Journal of Heart Failure, 2006, 8, 321-325. | 2.9 | 51 |
| 359 | Predictors of short term mortality in heart failure — Insights from the Euro Heart Failure survey. International Journal of Cardiology, 2010, 138, 63-69. | 0.8 | 51 |
| 360 | Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. Heart Failure Reviews, 2013, 18, 107-122. | 1.7 | 51 |

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 361 | Breathlessness at rest is not the dominant presentation of patients admitted with heart failure. European Journal of Heart Failure, 2014, 16, 1283-1291. | 2.9 | 51 |
| 362 | Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure. Circulation: Heart Failure, 2016, 9, . | 1.6 | 51 |
| 363 | Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm. JAMA Cardiology, 2019, 4, 515. | 3.0 | 51 |
| 364 | Global Differences in Characteristics, Precipitants, and Initial Management of Patients Presenting With Acute Heart Failure. JAMA Cardiology, 2020, 5, 401. | 3.0 | 51 |
| 365 | The prevalence and incidence of left bundle branch block in ambulant patients with chronic heart failure. European Journal of Heart Failure, 2008, 10, 696-702. | 2.9 | 50 |
| 366 | Diagnosis of elderly patients with heart failure. European Journal of Heart Failure, 2012, 14, 1097-1103. | 2.9 | 50 |
| 367 | The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure. American Heart Journal, 1986, 112, 130-135. | 1.2 | 49 |
| 368 | Impaired Pulmonary Diffusion During Exercise in Patients With Chronic Heart Failure. Circulation, 1999, 100, 1406-1410. | 1.6 | 49 |
| 369 | Levosimendan: a new era for inodilator therapy for heart failure?. Current Opinion in Cardiology, 2002, 17, 257-265. | 0.8 | 49 |
| 370 | Does the physical examination still have a role in patients with suspected heart failure?. European Journal of Heart Failure, 2011, 13, 1340-1348. | 2.9 | 49 |
| 371 | Sexâ€specific acute heart failure phenotypes and outcomes from PROTECT. European Journal of Heart Failure, 2013, 15, 1374-1381. | 2.9 | 49 |
| 372 | Patient journey after admission for acute heart failure: length of stay, 30â€day readmission and 90â€day mortality. European Journal of Heart Failure, 2016, 18, 1041-1050. | 2.9 | 49 |
| 373 | Telemedicine in heart failure: new insights from the Cochrane metaâ€analyses. European Journal of Heart Failure, 2017, 19, 304-306. | 2.9 | 49 |
| 374 | Internet-based training of coronary artery patients: the Heart Cycle Trial. Heart and Vessels, 2017, 32, 408-418. | 0.5 | 49 |
| 375 | Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. European Journal of Heart Failure, 2020, 22, 1649-1658. | 2.9 | 49 |
| 376 | Effect of Transcatheter Aortic Valve Implantation vs Surgical Aortic Valve Replacement on All-Cause Mortality in Patients With Aortic Stenosis. JAMA - Journal of the American Medical Association, 2022, 327, 1875. | 3.8 | 49 |
| 377 | Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH. European Journal of Heart Failure, 2002, 4, 111-116. | 2.9 | 48 |
| 378 | Atherosclerotic renovascular disease in chronic heart failure: should we intervene?. European Heart Journal, 2005, 26, 1596-1605. | 1.0 | 48 |

| # | Article | IF | CITATIONS |
|-----|--|--------------------|-----------|
| 379 | The Task Force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: full text (update) Tj ETQq1 1 0.784 | 4 3104 rgBT | /@verlock |
| 380 | Practical Applications of Intravenous Diuretic Therapy in Decompensated Heart Failure. American Journal of Medicine, 2006, 119, S26-S36. | 0.6 | 48 |
| 381 | Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus. Heart, 2009, 95, 917-923. | 1.2 | 48 |
| 382 | Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group. American Heart Journal, 2009, 157, 957-970. | 1.2 | 48 |
| 383 | Minimally clinically important difference in chronic breathlessness: Every little helps. American Heart Journal, 2012, 164, 229-235. | 1.2 | 48 |
| 384 | Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. Heart Failure Reviews, 2014, 19, 135-152. | 1.7 | 48 |
| 385 | Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the <scp>PROTECT</scp> trial. European Journal of Heart Failure, 2015, 17, 109-118. | 2.9 | 48 |
| 386 | Importance of Angina in Patients With Coronary Disease, Heart Failure, and LeftÂVentricular Systolic Dysfunction. Journal of the American College of Cardiology, 2015, 66, 2092-2100. | 1.2 | 48 |
| 387 | Renal function estimation and Cockcroft–Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart â€~OMics' in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. BMC Medicine, 2016, 14, 181. | 2.3 | 48 |
| 388 | Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE. European Journal of Heart Failure, 2005, 7, 1070-1075. | 2.9 | 47 |
| 389 | The burden of proof: The current state of atrial fibrillation prevention and treatment trials. Heart Rhythm, 2017, 14, 763-782. | 0.3 | 47 |
| 390 | Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. European Heart Journal, 2018, 39, 3867-3875. | 1.0 | 47 |
| 391 | Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: <scp>GALACTICâ€HF</scp> baseline characteristics and comparison with contemporary clinical trials. European Journal of Heart Failure, 2020, 22, 2160-2171. | 2.9 | 47 |
| 392 | Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study. European Heart Journal, 2001, 22, 1601-1612. | 1.0 | 46 |
| 393 | High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality. European Journal of Heart Failure, 2021, 23, 919-932. | 2.9 | 46 |
| 394 | Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. JACC: Heart Failure, 2021, 9, 268-277. | 1.9 | 46 |
| 395 | For Debate: Preventing atherosclerotic events with aspirin. BMJ: British Medical Journal, 2002, 324, 103-105. | 2.4 | 45 |
| 396 | Relation of sex, age and concomitant diseases to drug prescription for heart failure in primary care in Europe. European Journal of Heart Failure, 2004, 6, 663-668. | 2.9 | 45 |

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 397 | Once-Monthly Administration of Darbepoetin Alfa for the Treatment of Patients with Chronic Heart Failure and Anemia. Journal of Cardiovascular Pharmacology, 2005, 46, 155-161. | 0.8 | 45 |
| 398 | Repeat Dose Opioids May Be Effective for Breathlessness in Chronic Heart Failure if Given for Long Enough. Journal of Palliative Medicine, 2013, 16, 250-255. | 0.6 | 45 |
| 399 | Should all patients with atrial fibrillation receive warfarin? Evidence from randomized clinical trials. European Heart Journal, 1996, 17, 674-681. | 1.0 | 44 |
| 400 | Clinical trials update: IMPROVEMENT-HF, COPERNICUS, MUSTIC, ASPECT-II, APRICOT and HEART. European Journal of Heart Failure, 2000, 2, 455-460. | 2.9 | 44 |
| 401 | Oral levosimendan in patients with severe chronic heart failure—The PERSIST study. European Journal of Heart Failure, 2008, 10, 1246-1254. | 2.9 | 44 |
| 402 | Worsening Heart Failure Following Admission for Acute Heart Failure. JACC: Heart Failure, 2015, 3, 395-403. | 1.9 | 44 |
| 403 | The promotion of intrauterine contraception in low- and middle-income countries: a narrative review. Contraception, 2017, 95, 519-528. | 0.8 | 44 |
| 404 | Novel endotypes in heart failure: effects on guideline-directed medical therapy. European Heart Journal, 2018, 39, 4269-4276. | 1.0 | 44 |
| 405 | Renal response to candoxatrilat in patients with heart failure. Journal of the American College of Cardiology, 1995, 25, 1273-1281. | 1.2 | 43 |
| 406 | Effect of Supine Posture on Respiratory Mechanics in Chronic Left Ventricular Failure. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 1285-1291. | 2.5 | 43 |
| 407 | An evaluation of two self-report screening measures for mood in an out-patient chronic heart failure population. International Journal of Geriatric Psychiatry, 2007, 22, 1147-1153. | 1.3 | 43 |
| 408 | The Cholesterol Paradox in Heart Failure. Congestive Heart Failure, 2007, 13, 336-341. | 2.0 | 43 |
| 409 | Sildenafil in Heart Failure (SilHF). An investigatorâ€initiated multinational randomized controlled clinical trial: rationale and design. European Journal of Heart Failure, 2013, 15, 119-122. | 2.9 | 43 |
| 410 | Exercise Capacity and Mortality in Patients With Ischemic Left Ventricular Dysfunction Randomized to Coronary Artery Bypass Graft Surgery or Medical Therapy. JACC: Heart Failure, 2014, 2, 335-343. | 1.9 | 43 |
| 411 | Contraceptive Adoption, Discontinuation, and Switching among Postpartum Women in Nairobi's Urban Slums. Studies in Family Planning, 2015, 46, 369-386. | 1.0 | 43 |
| 412 | Should Î ² -Blockers Be Used in Patients With Heart Failure and Atrial Fibrillation?. Clinical Therapeutics, 2015, 37, 2215-2224. | 1.1 | 43 |
| 413 | The PCSK9-LDL Receptor Axis andÂOutcomes in Heart Failure. Journal of the American College of Cardiology, 2017, 70, 2128-2136. | 1.2 | 43 |
| 414 | Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients With Heart Failure. JAMA Cardiology, 2019, 4, 696. | 3.0 | 43 |

| # | Article | lF | CITATIONS |
|-----|---|-----|-----------|
| 415 | Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proofâ€ofâ€concept, randomised, precisionâ€medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. European Journal of Heart Failure, 2020, 22, 1711-1723. | 2.9 | 43 |
| 416 | Total body electrolyte composition in patients with heart failure: a comparison with normal subjects and patients with untreated hypertension Heart, 1987, 58, 230-238. | 1.2 | 42 |
| 417 | The effects of long-term β-blockade on the ventilatory responses to exercise in chronic heart failure. European Journal of Heart Failure, 2005, 7, 612-617. | 2.9 | 42 |
| 418 | Comparison of the dual receptor endothelin antagonist enrasentan with enalapril in asymptomatic left ventricular systolic dysfunction: a cardiovascular magnetic resonance study. Heart, 2005, 92, 798-803. | 1.2 | 42 |
| 419 | ACC/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2005, 46, 1179-1207. | 1.2 | 42 |
| 420 | Clinical trials update from the European Society of Cardiology Meeting 2009: AAA, RELY, PROTECT, ACTIVEâ€I, European CRT survey, German preâ€SCD II registry, and MADITâ€CRT. European Journal of Heart Failure, 2009, 11, 1214-1219. | 2.9 | 42 |
| 421 | Soluble Glycoprotein 130 Predicts Fatal Outcomes in Chronic Heart Failure. Circulation: Heart Failure, 2013, 6, 91-98. | 1.6 | 42 |
| 422 | Provider and lay perspectives on intra-uterine contraception: a global review. Reproductive Health, 2017, 14, 119. | 1.2 | 42 |
| 423 | Absence of Myocardial Fibrosis Predicts Favorable Long-Term Survival in New-Onset Heart Failure. Circulation: Cardiovascular Imaging, 2018, 11, e007722. | 1.3 | 42 |
| 424 | A Fresh Look at the Level of Unmet Need for Family Planning in the Postpartum Period, Its Causes and Program Implications. International Perspectives on Sexual and Reproductive Health, 2015, 41, 155-162. | 3.8 | 42 |
| 425 | Enhanced external counterpulsation for the treatment of stable angina and heart failure: a systematic review and economic analysis. Health Technology Assessment, 2009, 13, iii-iv, ix-xi, 1-90. | 1.3 | 42 |
| 426 | Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition. European Heart Journal, 2008, 29, 413-421. | 1.0 | 41 |
| 427 | Telemonitoring after discharge from hospital with heart failure: cost-effectiveness modelling of alternative service designs. BMJ Open, 2013, 3, e003250. | 0.8 | 41 |
| 428 | Prognostic significance of ultrasound-assessed jugular vein distensibility in heart failure. Heart, 2015, 101, 1149-1158. | 1.2 | 41 |
| 429 | Risk for Incident Heart Failure: A Subject‣evel Metaâ€Analysis From the Heart "OMics―in AGEing (HOMAGE) Study. Journal of the American Heart Association, 2017, 6, . | 1.6 | 41 |
| 430 | ACE inhibitors for heart failure: a question of dose. Heart, 1994, 72, S106-S110. | 1.2 | 40 |
| 431 | Elevated plasma endothelin concentrations in heart failure; an effect of angiotensin II?. European Heart Journal, 1994, 15, 1634-1640. | 1.0 | 40 |
| 432 | Management Strategies for a Better Outcome in Unstable Coronary Artery Disease. Clinical Cardiology, 1998, 21, 314-322. | 0.7 | 40 |

| # | Article | IF | CITATIONS |
|-----|--|-------------------|----------------|
| 433 | Longitudinal myocardial dysfunction in healthy older subjects as a manifestation of cardiac ageing. Age and Ageing, 2005, 34, 343-349. | 0.7 | 40 |
| 434 | The Safety of an Adenosine A1-Receptor Antagonist, Rolofylline, in Patients with Acute Heart Failure and Renal Impairment. Drug Safety, 2012, 35, 233-244. | 1.4 | 40 |
| 435 | The Long-Term Prognostic Significance of 6-Minute Walk Test Distance in Patients with Chronic Heart Failure. BioMed Research International, 2014, 2014, 1-7. | 0.9 | 40 |
| 436 | Fatigue as a Predictor of Outcome in Patients With Heart Failure. JACC: Heart Failure, 2014, 2, 187-197. | 1.9 | 40 |
| 437 | An m-Health system for education and motivation in cardiac rehabilitation: the experience of HeartCycle guided exercise. Journal of Telemedicine and Telecare, 2018, 24, 303-316. | 1.4 | 40 |
| 438 | GuÃa ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. Revista Espanola De Cardiologia, 2022, 75, 523.e1-523.e114. | 0.6 | 40 |
| 439 | Increasing awareness and improving the management of heart failure in Europe: the IMPROVEMENT of HF initiative. European Journal of Heart Failure, 1999, 1, 139-144. | 2.9 | 39 |
| 440 | Effect of Cardiac Resynchronization on Morbidity and Mortality of Diabetic Patients With Severe Heart Failure. Diabetes Care, 2007, 30, 722-724. | 4.3 | 39 |
| 441 | The Challenges Posed by Demographic Change in subâ€Saharan Africa: A Concise Overview. Population and Development Review, 2017, 43, 264-286. | 1.2 | 39 |
| 442 | Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH) Tj ETQq0 0 (|) rgBT /Ov 0.7 | erlggk 10 Tf 5 |
| 443 | Impact of Renal Impairment on Beta-Blocker Efficacy in PatientsÂWithÂHeartÂFailure. Journal of the American College of Cardiology, 2019, 74, 2893-2904. | 1.2 | 39 |
| 444 | Intravenous iron for heart failure with evidence of iron deficiency: a meta-analysis of randomised trials. Clinical Research in Cardiology, 2021, 110, 1299-1307. | 1.5 | 39 |
| 445 | A systematic review and meta-analysis of beta-blockers and renin–angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer. European Heart Journal, 2022, 43, 2562-2569. | 1.0 | 39 |
| 446 | Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. Journal of Cardiac Failure, 1998, 4, 3-8. | 0.7 | 38 |
| 447 | Outcome Studies with Device Therapy in Patients with Heart Failure. Journal of Cardiovascular Electrophysiology, 2002, 13, S73-91. | 0.8 | 38 |
| 448 | How to assess new treatments for the management of heart failure: composite scoring systems to assess the patients' clinical journey. European Journal of Heart Failure, 2002, 4, 243-247. | 2.9 | 38 |
| 449 | Excessive breathlessness in patients with diastolic heart failure. Heart, 2006, 92, 1425-1429. | 1.2 | 38 |
| 450 | Thyroid-Stimulating Hormone and Clinical Outcomes. JACC: Heart Failure, 2014, 2, 35-40. | 1.9 | 38 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 451 | Bone marrow iron depletion is common in patients with coronary artery disease. International Journal of Cardiology, 2015, 182, 517-522. | 0.8 | 38 |
| 452 | Rationale and design of the randomized multicentre His Optimized Pacing Evaluated for Heart Failure (HOPEâ€HF) trial. ESC Heart Failure, 2018, 5, 965-976. | 1.4 | 38 |
| 453 | Myocardial injury in severe COVID-19 infection. European Heart Journal, 2020, 41, 2080-2082. | 1.0 | 38 |
| 454 | Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial. European Journal of Heart Failure, 2003, 5, 101-108. | 2.9 | 37 |
| 455 | The benefits of educating women. Lancet, The, 2010, 376, 933-934. | 6.3 | 37 |
| 456 | Clinical Trials in Patients with Heart Failure and Preserved Left Ventricular Ejection Fraction. Heart Failure Clinics, 2014, 10, 511-523. | 1.0 | 37 |
| 457 | Telemonitoring in heart failure: Big Brother watching over you. Heart Failure Reviews, 2015, 20, 107-116. | 1.7 | 37 |
| 458 | New perspectives and future directions in the treatment of heart failure. Heart Failure Reviews, 2020, 25, 147-159. | 1.7 | 37 |
| 459 | Arrhythmias, catecholamines and electrolytes. American Journal of Cardiology, 1988, 62, 55A-59A. | 0.7 | 36 |
| 460 | Effect of carvedilol and metoprolol on the mode of death in patients with heart failure. European Journal of Heart Failure, 2007, 9, 1128-1135. | 2.9 | 36 |
| 461 | Clinical trials update from the American College of Cardiology 2007: ALPHA, EVEREST, FUSION II, VALIDD, PARR-2, REMODEL, SPICE, COURAGE, COACH, REMADHE, pro-BNP for the evaluation of dyspnoea and THIS-diet. European Journal of Heart Failure, 2007, 9, 740-745. | 2.9 | 36 |
| 462 | Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study. European Heart Journal, 2009, 30, 2109-2116. | 1.0 | 36 |
| 463 | Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure, 2015, 17, 169-176. | 2.9 | 36 |
| 464 | Temporal trends in the incidence, treatment patterns, and outcomes of coronary artery disease and peripheral artery disease in the UK, 2006â \in "2015. European Heart Journal, 2020, 41, 1636-1649. | 1.0 | 36 |
| 465 | Diabetes Lowers Six-Minute Walk Test Performance in Heart Failure. Journal of the American College of Cardiology, 2006, 47, 1909-1910. | 1.2 | 35 |
| 466 | Influence of step length on 6-minute walk test performance in patients with chronic heart failure. Physiotherapy, 2012, 98, 325-329. | 0.2 | 35 |
| 467 | The relation between repeated 6-minute walk test performance and outcome in patients with chronic heart failure. Annals of Physical and Rehabilitation Medicine, 2014, 57, 244-253. | 1.1 | 35 |
| 468 | Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. Circulation: Heart Failure, 2016, 9, . | 1.6 | 35 |

| # | Article | IF | CITATIONS |
|-----|--|------|-----------|
| 469 | MicroRNAs relate to early worsening of renal function in patients with acute heart failure. International Journal of Cardiology, 2016, 203, 564-569. | 0.8 | 35 |
| 470 | The role of angiotensin receptor–neprilysin inhibitors in cardiovascular disease—existing evidence, knowledge gaps, and future directions. European Journal of Heart Failure, 2018, 20, 963-972. | 2.9 | 35 |
| 471 | Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure. Journal of the American College of Cardiology, 2018, 71, 386-398. | 1.2 | 35 |
| 472 | Conduct of Clinical Trials in the Era of COVID-19. Journal of the American College of Cardiology, 2020, 76, 2368-2378. | 1.2 | 35 |
| 473 | Diastolic heart failure. Paroxysmal or chronic?. European Journal of Heart Failure, 2004, 6, 427-431. | 2.9 | 34 |
| 474 | Predictors of Mortality From Pump Failure and Sudden Cardiac Death in Patients With Systolic Heart Failure and Left Ventricular Dyssynchrony: Results of the CARE-HF Trial. Journal of Cardiac Failure, 2008, 14, 670-675. | 0.7 | 34 |
| 475 | Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. International Journal of Cardiology, 2016, 204, 164-171. | 0.8 | 34 |
| 476 | Plasma biomarkers to predict or rule out early postâ€discharge events after hospitalization for acute heart failure. European Journal of Heart Failure, 2017, 19, 728-738. | 2.9 | 34 |
| 477 | Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with midâ€range and preserved ejection fraction. European Journal of Heart Failure, 2017, 19, 1690-1697. | 2.9 | 34 |
| 478 | Worsening renal function in acute heart failure in the context of diuretic response. European Journal of Heart Failure, 2022, 24, 365-374. | 2.9 | 34 |
| 479 | Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity. British Journal of Clinical Pharmacology, 2003, 57, 188-198. | 1.1 | 33 |
| 480 | What would Malthus say about AIDS in Africa?. Lancet, The, 2005, 366, 1899-1901. | 6.3 | 33 |
| 481 | Baseline echocardiographic characteristics of heart failure patients enrolled in a large European multicentre trial (CArdiac REsynchronisation Heart Failure study). European Journal of Echocardiography, 2006, 7, 373-378. | 2.3 | 33 |
| 482 | Clinical trials update from the American Heart Association 2006: OAT, SALT 1 and 2, MAGIC, ABCD, PABA-CHF, IMPROVE-CHF, and percutaneous mitral annuloplasty. European Journal of Heart Failure, 2007, 9, 92-97. | 2.9 | 33 |
| 483 | Telemonitoring in Patients with Heart Failure. New England Journal of Medicine, 2011, 364, 1078-1080. | 13.9 | 33 |
| 484 | Defining Diastolic Heart Failure and Identifying Effective Therapies. JAMA - Journal of the American Medical Association, 2013, 309, 825. | 3.8 | 33 |
| 485 | Revisiting a classical clinical sign: Jugular venous ultrasound. International Journal of Cardiology, 2014, 170, 364-370. | 0.8 | 33 |
| 486 | Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin. Indian Heart Journal, 2018, 70, S96-S100. | 0.2 | 33 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 487 | Association of Fitness and Grip Strength With Heart Failure. Mayo Clinic Proceedings, 2019, 94, 2230-2240. | 1.4 | 33 |
| 488 | Clinical value of preâ€discharge bioâ€adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission. European Journal of Heart Failure, 2020, 22, 683-691. | 2.9 | 33 |
| 489 | Serum uric acid, influence of sacubitril–valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: <scp>PARAGONâ€HF</scp> . European Journal of Heart Failure, 2020, 22, 2093-2101. | 2.9 | 33 |
| 490 | Home monitoring with technology-supported management in chronic heart failure: a randomised trial. Heart, 2020, 106, 1573-1578. | 1.2 | 33 |
| 491 | An Explainable Transformer-Based Deep Learning Model for the Prediction of Incident Heart Failure. IEEE Journal of Biomedical and Health Informatics, 2022, 26, 3362-3372. | 3.9 | 33 |
| 492 | A cross national study of patterns of sexual behaviour. Journal of Sex Research, 1989, 26, 287-299. | 1.6 | 32 |
| 493 | The control of adrenergic function in heart failure: therapeutic intervention. , 2000, 5, 101-114. | | 32 |
| 494 | Are beta-blockers effective in patients who develop heart failure soon after myocardial infarction? A meta-regression analysis of randomised trials. European Journal of Heart Failure, 2000, 2, 333-340. | 2.9 | 32 |
| 495 | Endothelin antagonists for chronic heart failure: do they have a role?. European Heart Journal, 2001, 22, 1772-1784. | 1.0 | 32 |
| 496 | The immediate and long-term outcome of enhanced external counterpulsation in treatment of chronic stable refractory angina. Journal of Internal Medicine, 2006, 259, 276-284. | 2.7 | 32 |
| 497 | Renal Sympathetic Denervation Therapy for Resistant Hypertension. Circulation: Cardiovascular Interventions, 2013, 6, 184-197. | 1.4 | 32 |
| 498 | Is age a factor in the success or failure of remote monitoring in heart failure? Telemonitoring and structured telephone support in elderly heart failure patients. European Journal of Cardiovascular Nursing, 2015, 14, 248-255. | 0.4 | 32 |
| 499 | Plasma kidney injury moleculeâ€1 in heart failure: renal mechanisms and clinical outcome. European Journal of Heart Failure, 2016, 18, 641-649. | 2.9 | 32 |
| 500 | A combined clinical and biomarker approach to predict diuretic response in acute heart failure. Clinical Research in Cardiology, 2016, 105, 145-153. | 1.5 | 32 |
| 501 | Diagnostic tests, drug prescriptions, and follow-up patterns after incident heart failure: A cohort study of 93,000 UK patients. PLoS Medicine, 2019, 16, e1002805. | 3.9 | 32 |
| 502 | The year in cardiology 2018: heart failure. European Heart Journal, 2019, 40, 651-661. | 1.0 | 32 |
| 503 | Impact of mitral regurgitation in patients with worsening heart failure: insights from <scp>BIOSTAT HF</scp> . European Journal of Heart Failure, 2021, 23, 1750-1758. | 2.9 | 32 |
| 504 | Methodological Shortcomings of Wrist-Worn Heart Rate Monitors Validations. Journal of Medical Internet Research, 2018, 20, e10108. | 2.1 | 32 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 505 | Early Indication of Decompensated Heart Failure in Patients on Home-Telemonitoring: A Comparison of Prediction Algorithms Based on Daily Weight and Noninvasive Transthoracic Bio-impedance. JMIR Medical Informatics, 2016, 4, e3. | 1.3 | 32 |
| 506 | Cardioreparation and the Concept of Modulating Cardiovascular Structure and Function. Blood Pressure, 1993, 2, 6-21. | 0.7 | 31 |
| 507 | Assessment and diagnosis of heart failure. Journal of Internal Medicine, 1996, 239, 317-325. | 2.7 | 31 |
| 508 | Perception of symptoms is out of proportion to cardiac pathology in patients with "diastolic heart failure". Heart, 2008, 94, 748-753. | 1.2 | 31 |
| 509 | Right and left bundle branch block as predictors of longâ€ŧerm mortality following myocardial infarction. European Journal of Heart Failure, 2011, 13, 1349-1354. | 2.9 | 31 |
| 510 | Identifying patients at risk of death or hospitalisation due to worsening heart failure using decision tree analysis: Evidence from the Trans-European Network-Home-Care Management System (TEN-HMS) Study. International Journal of Cardiology, 2013, 163, 149-156. | 0.8 | 31 |
| 511 | The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter defibrillator therapy: who benefits the most?. European Heart Journal, 2015, 36, 1676-1688. | 1.0 | 31 |
| 512 | An electronic health records cohort study on heart failure following myocardial infarction in England: incidence and predictors. BMJ Open, 2018, 8, e018331. | 0.8 | 31 |
| 513 | Development and course of heart failure after a myocardial infarction in younger and older people. Journal of Geriatric Cardiology, 2014, 11, 1-12. | 0.2 | 31 |
| 514 | Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. European Journal of Heart Failure, 2000, 2, 447-454. | 2.9 | 30 |
| 515 | The diagnosis of heart failure in European primary care: The IMPROVEMENT Programme survey of perception and practice. European Journal of Heart Failure, 2005, 7, 768-779. | 2.9 | 30 |
| 516 | Metabolic remodeling in the aging heart. Journal of Molecular and Cellular Cardiology, 2006, 40, 56-63. | 0.9 | 30 |
| 517 | Thiazolidinediones, deadly sins, surrogates, and elephants. Lancet, The, 2007, 370, 1103-1104. | 6.3 | 30 |
| 518 | The effect of pharmacological stress on intraventricular dyssynchrony in left ventricular systolic dysfunction. European Journal of Heart Failure, 2008, 10, 412-420. | 2.9 | 30 |
| 519 | Not all systematic reviews are systematic: a meta-review of the quality of systematic reviews for non-invasive remote monitoring in heart failure. Journal of Telemedicine and Telecare, 2013, 19, 326-337. | 1.4 | 30 |
| 520 | Perceived norms of premarital heterosexual relationships and sexuality among female college students in Tehran. Culture, Health and Sexuality, 2015, 17, 700-717. | 1.0 | 30 |
| 521 | Reflections on EchoCRT: sound guidance on QRS duration and morphology for CRT?: Figure 1. European Heart Journal, 2015, 36, 1948-1951. | 1.0 | 30 |
| 522 | Limited Added Value of CirculatingÂInflammatory Biomarkers inÂChronic HeartÂFailure. JACC: Heart Failure, 2017, 5, 256-264. | 1.9 | 30 |

| # | Article | IF | CITATIONS |
|-----|---|------------|--------------|
| 523 | Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure. Journal of Cardiac Failure, 2017, 23, 231-239. | 0.7 | 30 |
| 524 | Proteomic diversity of highâ€density lipoprotein explains its association with clinical outcome in patients with heart failure. European Journal of Heart Failure, 2018, 20, 260-267. | 2.9 | 30 |
| 525 | A current and future outlook on upcoming technologies in remote monitoring of patients with heart failure. European Journal of Heart Failure, 2021, 23, 175-185. | 2.9 | 30 |
| 526 | Diabetes and preâ€diabetes in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 2022, 24, 497-509. | 2.9 | 30 |
| 527 | Clinical trials update from the American Heart Association meeting: Ω-3 fatty acids and arrhythmia risk in patients with an implantable defibrillator, ACTIV in CHF, VALIANT, the Hanover autologous bone marrow transplantation study, SPORTIF V, ORBIT and PA. European Journal of Heart Failure, 2004, 6, 109-115. | 2.9 | 29 |
| 528 | Exchange of β-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the) Tj ETQq0 | 0.0.rgBT / | /Oyerlock 10 |
| 529 | Effect of a community heart failure clinic on uptake of blockers by patients with obstructive airways disease and heart failure. Heart, 2005, 92, 331-336. | 1.2 | 29 |
| 530 | Successful treatment of heart failure with devices requires collaboration. European Journal of Heart Failure, 2008, 10, 1229-1235. | 2.9 | 29 |
| 531 | Enlisting the Help of the Largest Health Care Workforce—Patients. JAMA - Journal of the American Medical Association, 2010, 304, 1383. | 3.8 | 29 |
| 532 | ls aspirin useful in primary prevention?. European Heart Journal, 2013, 34, 3412-3418. | 1.0 | 29 |
| 533 | Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors in hypertension or heart failure?. Current Opinion in Nephrology and Hypertension, 2001, 10, 625-631. | 1.0 | 28 |
| 534 | Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans. European Journal of Heart Failure, 2003, 5, 391-398. | 2.9 | 28 |
| 535 | Nonpharmacologic Measures and Drug Compliance in Patients with Heart Failure: Data from the EuroHeart Failure Survey. American Journal of Cardiology, 2007, 99, S31-S37. | 0.7 | 28 |
| 536 | The prognostic value of cardiopulmonary exercise testing with a peak respiratory exchange ratio of <1.0 in patients with chronic heart failure. International Journal of Cardiology, 2008, 127, 88-92. | 0.8 | 28 |
| 537 | Anticoagulation in heart failure: current status and future direction. Heart Failure Reviews, 2013, 18, 797-813. | 1.7 | 28 |
| 538 | Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the <scp>VERITAS</scp> study. European Journal of Heart Failure, 2014, 16, 1362-1371. | 2.9 | 28 |
| 539 | Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure—does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (<scp>VERITAS</scp>). European Journal of Heart Failure. 2017. 19. 739-747. | 2.9 | 28 |
| 540 | Nonâ€invasive measurement of right atrial pressure by nearâ€infrared spectroscopy: preliminary experience. A report from the <scp>SICAâ€HF</scp> study. European Journal of Heart Failure, 2017, 19, 883-892. | 2.9 | 28 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 541 | Women's attitudes and beliefs towards specific contraceptive methods in Bangladesh and Kenya. Reproductive Health, 2018, 15, 75. | 1.2 | 28 |
| 542 | Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure. Heart, 2019, 105, 307-314. | 1.2 | 28 |
| 543 | Oral modified release morphine for breathlessness in chronic heart failure: a randomized placebo ontrolled trial. ESC Heart Failure, 2019, 6, 1149-1160. | 1.4 | 28 |
| 544 | The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. Clinical Research in Cardiology, 2020, 109, 331-338. | 1.5 | 28 |
| 545 | Plasma proteomic approach in patients withÂheart failure: insights into pathogenesis ofÂdisease progression and potential novel treatment targets. European Journal of Heart Failure, 2020, 22, 70-80. | 2.9 | 28 |
| 546 | A network analysis to identify pathophysiological pathways distinguishing ischaemic from nonâ€ischaemic heart failure. European Journal of Heart Failure, 2020, 22, 821-833. | 2.9 | 28 |
| 547 | Heart Failure due to Ischaemic Heart Disease: Epidemiology, Pathophysiology and Progression. Journal of Cardiovascular Pharmacology, 1999, 33, S17-S29. | 0.8 | 28 |
| 548 | Comparison of selective ETAand ETBreceptor antagonists in patients with chronic heart failure. European Journal of Heart Failure, 2005, 7, 37-42. | 2.9 | 27 |
| 549 | Clinical trials update from the European Society of Cardiology heart failure meeting: TNT subgroup analysis, darbepoetin alfa, FERRIC-HF and KW-3902. European Journal of Heart Failure, 2006, 8, 547-549. | 2.9 | 27 |
| 550 | Impact of different diagnostic criteria on the prevalence and prognostic significance of exertional oscillatory ventilation in patients with chronic heart failure. European Journal of Cardiovascular Prevention and Rehabilitation, 2009, 16, 451-456. | 3.1 | 27 |
| 551 | Unconventional End Points in Cardiovascular Clinical Trials: Should We Be Moving Away From Morbidity and Mortality?. Journal of Cardiac Failure, 2009, 15, 199-205. | 0.7 | 27 |
| 552 | Influence of Crossover on Mortality in a Randomized Study of Revascularization in Patients With Systolic Heart Failure and Coronary Artery Disease. Circulation: Heart Failure, 2013, 6, 443-450. | 1.6 | 27 |
| 553 | Depression as an independent prognostic factor for all-cause mortality after a hospital admission for worsening heart failure. International Journal of Cardiology, 2016, 220, 202-207. | 0.8 | 27 |
| 554 | Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS. Journal of Cardiac Failure, 2016, 22, 815-822. | 0.7 | 27 |
| 555 | Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure. Clinical Research in Cardiology, 2017, 106, 711-721. | 1.5 | 27 |
| 556 | Predictors of shortâ€ŧerm clinical response to cardiac resynchronization therapy. European Journal of Heart Failure, 2017, 19, 1056-1063. | 2.9 | 27 |
| 557 | Tumour biomarkers: association with heart failure outcomes. Journal of Internal Medicine, 2020, 288, 207-218. | 2.7 | 27 |
| 558 | Predictors of left ventricular remodelling in patients with dilated cardiomyopathy – a cardiovascular magnetic resonance study. European Journal of Heart Failure, 2020, 22, 1160-1170. | 2.9 | 27 |

| # | Article | IF | CITATIONS |
|-----|--|---------------------|----------------|
| 559 | Clinical trials update from the American College of Cardiology 2009: ADMIREâ€HF, PRIMA, STICH, REVERSE, IRIS, partial ventricular support, FIXã€HFâ€5, vagal stimulation, REVIVALâ€3, preâ€RELAXâ€AHF, ACT HFâ€ACTION, JUPITER, AURORA, and OMEGA. European Journal of Heart Failure, 2009, 11, 622-630. | IVEâ€ A , | 26 |
| 560 | Adherence to self-care in patients with heart failure in the HeartCycle study. Patient Preference and Adherence, 2015, 9, 1195. | 0.8 | 26 |
| 561 | Hyperkalemia and Treatment With RAASÂInhibitors During Acute HeartÂFailure Hospitalizations and TheirÂAssociation With Mortality. JACC: Heart Failure, 2019, 7, 970-979. | 1.9 | 26 |
| 562 | Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Heart Failure Reviews, 2021, 26, 1421-1435. | 1.7 | 26 |
| 563 | Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure. European Journal of Heart Failure, 2022, 24, 807-817. | 2.9 | 26 |
| 564 | Heart failure: a medical hydra. Lancet, The, 1998, 352, SI1-SI2. | 6.3 | 25 |
| 565 | Î2-Blockers for heart failure: why, which, when, and where. Medical Clinics of North America, 2003, 87, 339-371. | 1.1 | 25 |
| 566 | A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1) Tj ETO | Qq0 @ 70 rgE | 3T /Øverlock 1 |
| 567 | Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure. Expert Review of Cardiovascular Therapy, 2004, 2, 9-19. | 0.6 | 25 |
| 568 | The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology: Guidelines for the Diagnosis and Treatment of Chronic Heart Failure: reply. European Heart Journal, 2005, 26, 2473-2474. | 1.0 | 25 |
| 569 | Predicting peak oxygen uptake from 6-min walk test performance in male patients with left ventricular systolic dysfunction. European Journal of Heart Failure, 2006, 8, 198-202. | 2.9 | 25 |
| 570 | Is taking part in clinical trials good for your health? A cohort study. European Journal of Heart Failure, 2009, 11, 1078-1083. | 2.9 | 25 |
| 571 | Telemonitoring for heart failure: the only feasible option for good universal care?. European Journal of Heart Failure, 2009, 11, 227-228. | 2.9 | 25 |
| 572 | Specialist intervention is associated with improved patient outcomes in patients with decompensated heart failure: evaluation of the impact of a multidisciplinary inpatient heart failure team. Open Heart, 2017, 4, e000547. | 0.9 | 25 |
| 573 | Prevalence, predictors, and prognostic implications of PR interval prolongation in patients with heart failure. Clinical Research in Cardiology, 2018, 107, 108-119. | 1.5 | 25 |
| 574 | Geographical location affects the levels and association of trimethylamine Nâ€oxide with heart failure mortality in BIOSTATâ€CHF: a postâ€hoc analysis. European Journal of Heart Failure, 2019, 21, 1291-1294. | 2.9 | 25 |
| 575 | Clinical correlates and outcome associated with changes in 6â€minute walking distance in patients with heart failure: findings from the BIOSTATâ€CHF study. European Journal of Heart Failure, 2019, 21, 218-226. | 2.9 | 25 |
| 576 | Expanding Method Choice in Africa with Long-Acting Methods: IUDs, Implants or Both?. International Perspectives on Sexual and Reproductive Health, 2017, 43, 183. | 3.8 | 25 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 577 | Left ventricular ejection fraction and volumes from gated blood-pool SPECT: comparison with planar gated blood-pool imaging and assessment of repeatability in patients with heart failure. Journal of Nuclear Medicine, 2003, 44, 494-8. | 2.8 | 25 |
| 578 | No reduction in cardiovascular risk with NSAIDs—including aspirin?. Lancet, The, 2002, 359, 92-93. | 6.3 | 24 |
| 579 | Declining In-Hospital Mortality and Increasing Heart Failure Incidence in Elderly Patients With First Myocardial Infarction. Journal of the American College of Cardiology, 2009, 55, 79-81. | 1.2 | 24 |
| 580 | Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial. European Journal of Heart Failure, 2015, 17, 697-706. | 2.9 | 24 |
| 581 | Prescribing Patterns to Optimize HeartÂRate. JACC: Heart Failure, 2015, 3, 224-230. | 1.9 | 24 |
| 582 | Unintended Childbearing and Child Growth in Northern Malawi. Maternal and Child Health Journal, 2017, 21, 467-474. | 0.7 | 24 |
| 583 | Effects of combined renin–angiotensin–aldosterone system inhibitor and betaâ€blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from <scp>BIOSTATâ€CHF</scp> and <scp>ASIANâ€HF</scp> registries. European Journal of Heart Failure, 2020, 22, 1472-1482. | 2.9 | 24 |
| 584 | Heart â€~omics' in AGEing (HOMAGE): design, research objectives and characteristics of the common database. Journal of Biomedical Research, 2014, 28, 349. | 0.7 | 24 |
| 585 | Precision Phenotyping of Dilated Cardiomyopathy Using Multidimensional Data. Journal of the American College of Cardiology, 2022, 79, 2219-2232. | 1.2 | 24 |
| 586 | The reversibility of increased airways resistance in chronic heart failure measured by impulse oscillometry. Journal of Cardiac Failure, 2004, 10, 149-154. | 0.7 | 23 |
| 587 | Clinical trials update from the American Heart Association 2007: CORONA, RethinQ, MASCOT, AF HF, HART, MASTER, POISE and stem cell therapy. European Journal of Heart Failure, 2008, 10, 102-108. | 2.9 | 23 |
| 588 | Limited role for ivabradine in the treatment of chronic heart failure. Heart, 2011, 97, 1961-1966. | 1.2 | 23 |
| 589 | It makes SENSE to take a safer road. European Heart Journal, 2011, 32, 2225-2227. | 1.0 | 23 |
| 590 | Exploring quality of life in patients with and without heart failure. International Journal of Cardiology, 2016, 202, 676-684. | 0.8 | 23 |
| 591 | Use of diuretics and outcomes in patients with type 2 diabetes: findings from the <scp>EMPAâ€REG OUTCOME</scp> trial. European Journal of Heart Failure, 2021, 23, 1085-1093. | 2.9 | 23 |
| 592 | Micronutrient deficiencies in heart failure: Mitochondrial dysfunction as a common pathophysiological mechanism?. Journal of Internal Medicine, 2022, 291, 713-731. | 2.7 | 23 |
| 593 | Modification of atherosclerosis by agents that do not lower cholesterol. Heart, 1993, 69, S54-S62. | 1.2 | 22 |
| 594 | Screening For Left Ventricular Dysfunction and Chronic Heart Failure. Disease Management and Health Outcomes, 1997, 1, 169-184. | 0.3 | 22 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 595 | The WASH study (Warfarin/Aspirin Study in Heart failure) rationale, design and end-points. European Journal of Heart Failure, 1999, 1, 95-99. | 2.9 | 22 |
| 596 | Clinical trials update from the European Society of Cardiology: CARMEN, EARTH, OPTIMAAL, ACE, TEN-HMS, MAGIC, SOLVD-X and PATH-CHF II. European Journal of Heart Failure, 2002, 4, 661-666. | 2.9 | 22 |
| 597 | Effects of applying a standardised management algorithm for moderate to severe renal dysfunction in patients with chronic stable heart failure. European Journal of Heart Failure, 2007, 9, 415-423. | 2.9 | 22 |
| 598 | Clinical assessment of acute heart failure syndromes: emergency department through the early post-discharge period. Heart, 2011, 97, 1607-1618. | 1.2 | 22 |
| 599 | Effects of reducing inspired oxygen concentration for one hour in patients with chronic heart failure: implications for air travel. European Journal of Heart Failure, 2013, 15, 505-510. | 2.9 | 22 |
| 600 | European Cardiac Resynchronization Therapy Survey II: rationale and design. Europace, 2015, 17, 137-141. | 0.7 | 22 |
| 601 | Hydralazine and nitrates alone or combined for the management of chronic heart failure: A systematic review. International Journal of Cardiology, 2015, 196, 61-69. | 0.8 | 22 |
| 602 | Xanthine oxidase inhibition for the treatment of cardiovascular disease: an updated systematic review and metaâ€analysis. ESC Heart Failure, 2017, 4, 40-45. | 1.4 | 22 |
| 603 | Prevalence and determinants of hypertension in apparently healthy schoolchildren in India: A multi-center study. European Journal of Preventive Cardiology, 2018, 25, 1775-1784. | 0.8 | 22 |
| 604 | Fertility preferences and subsequent childbearing in Africa and Asia: A synthesis of evidence from longitudinal studies in 28 populations. Population Studies, 2020, 74, 1-21. | 1.1 | 22 |
| 605 | Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis. Clinical Research in Cardiology, 2022, 111, 428-439. | 1.5 | 22 |
| 606 | Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction. European Heart Journal, 2022, 43, 2224-2234. | 1.0 | 22 |
| 607 | Effects of aging on neuroendocrine activation in subjects and patients in the presence and absence of heart failure with left ventricular systolic dysfunction. American Journal of Cardiology, 1996, 77, 1197-1201. | 0.7 | 21 |
| 608 | What is the optimal medical management of ischemic heart failure?. Progress in Cardiovascular Diseases, 2001, 43, 433-455. | 1.6 | 21 |
| 609 | Airway resistance in chronic heart failure measured by impulse oscillometry. Journal of Cardiac Failure, 2002, 8, 225-231. | 0.7 | 21 |
| 610 | The determinants of clinical outcome and clinical response to CRT are not the same. Heart Failure Reviews, 2012, 17, 755-766. | 1.7 | 21 |
| 611 | Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro–B-Type Natriuretic Peptide Level asÂPredictors of Outcomes in PatientsÂWithÂHeart Failure and PreservedAEjectionÂFraction. JACC: Heart Failure, 2015, 3, 478-486. | 1.9 | 21 |
| 612 | Referral for Specialist Follow-up and Its Association With Post-discharge Mortality Among Patients With Systolic Heart Failure (from the National Heart Failure Audit for England and Wales). American Journal of Cardiology, 2017, 119, 440-444. | 0.7 | 21 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 613 | Sudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting. Circulation, 2017, 135, 1136-1144. | 1.6 | 21 |
| 614 | Validation of U.S. mortality prediction models for hospitalized heart failure in the United Kingdom and Japan. European Journal of Heart Failure, 2018, 20, 1179-1190. | 2.9 | 21 |
| 615 | Myocardial viability testing: all STICHed up, or about to be REVIVED?. European Heart Journal, 2022, 43, 118-126. | 1.0 | 21 |
| 616 | How do ACE inhibitors reduce mortality in patients with left ventricular dysfunction with and without heart failure: remodelling, resetting, or sudden death?. Heart, 1994, 72, S81-S86. | 1.2 | 20 |
| 617 | Plasma neuro-endocrine activity in very elderly subjects and patients with and without heart failure. European Heart Journal, 1995, 16, 1223-1230. | 1.0 | 20 |
| 618 | Endothelin-1 has haemodynamic effects at pathophysiological concentrations in patients with left ventricular dysfunction. Cardiovascular Research, 1998, 39, 563-570. | 1.8 | 20 |
| 619 | Progression from Hypertension to Heart Failure. Cardiology, 1999, 92, 10-19. | 0.6 | 20 |
| 620 | The Carvedilol Hibernation Reversible Ischaemia Trial, Marker of Success (CHRISTMAS) study. International Journal of Cardiology, 2000, 72, 265-274. | 0.8 | 20 |
| 621 | Threats, opportunities, and statins in the modern management of heart failureThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology European Heart Journal, 2006, 27, 641-643. | 1.0 | 20 |
| 622 | The assessment of autonomic function in chronic atrial fibrillation: description of a non-invasive technique based on circadian rhythm of atrioventricular nodal functional refractory periods. Europace, 2006, 8, 927-934. | 0.7 | 20 |
| 623 | Clinical trials update from the American College of Cardiology: Darbepoetin alfa, ASTEROID, UNIVERSE, paediatric carvedilol, UNLOAD and ICELAND. European Journal of Heart Failure, 2006, 8, 326-329. | 2.9 | 20 |
| 624 | Prevalence of markers of heart failure in patients with atrial fibrillation and the effects of ximelagatran compared to warfarin on the incidence of morbid and fatal events: A report from the SPORTIF III and V trials. European Journal of Heart Failure, 2007, 9, 730-739. | 2.9 | 20 |
| 625 | Prognostic significance of different measures of the ventilationâ€earbon dioxide relation in patients with suspected heart failure. European Journal of Heart Failure, 2011, 13, 537-542. | 2.9 | 20 |
| 626 | Development of a composite model derived from cardiopulmonary exercise tests to predict mortality risk in patients with mild-to-moderate heart failure. Heart, 2014, 100, 781-786. | 1.2 | 20 |
| 627 | Issues in the Mining of Heart Failure Datasets. International Journal of Automation and Computing, 2014, 11, 162-179. | 4.5 | 20 |
| 628 | Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe?. European Journal of Heart Failure, 2018, 20, 317-322. | 2.9 | 20 |
| 629 | Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. European Journal of Heart Failure, 2019, 21, 1022-1031. | 2.9 | 20 |
| 630 | Primary Results of the Sensible Medical Innovations Lung Fluid Status Monitor Allows Reducing Readmission Rate of Heart Failure Patients (smile) Trial. Journal of Cardiac Failure, 2019, 25, 938. | 0.7 | 20 |

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 631 | Heart failure treatment upâ€titration and outcome and age: an analysis of BIOSTATâ€CHF. European Journal of Heart Failure, 2021, 23, 436-444. | 2.9 | 20 |
| 632 | Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. Clinical Research in Cardiology, 2020, 109, 1048-1059. | 1.5 | 20 |
| 633 | Additional burden of iron deficiency in heart failure patients beyond the cardioâ€renal anaemia syndrome: findings from the <scp>BIOSTATâ€CHF</scp> study. European Journal of Heart Failure, 2022, 24, 192-204. | 2.9 | 20 |
| 634 | Angiotensin converting enzyme inhibitors for hypertension and heart failure?. Postgraduate Medical Journal, 1992, 68, 1-5. | 0.9 | 19 |
| 635 | Natriuretic peptides for heart failure. Fashionable? Useful? Necessary?. European Journal of Heart Failure, 2004, 6, 253-255. | 2.9 | 19 |
| 636 | Cardiac resynchronization therapy or atrio-biventricular pacing—what should it be called?. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 90-101. | 3.3 | 19 |
| 637 | The effects of initiation or continuation of statin therapy on cholesterol level and all-cause mortality after the diagnosis of left ventricular systolic dysfunction. American Heart Journal, 2007, 153, 537-544. | 1.2 | 19 |
| 638 | Should We Be Trying to Define Responders to Cardiac Resynchronization Therapy?. JACC: Cardiovascular Imaging, 2010, 3, 541-549. | 2.3 | 19 |
| 639 | Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?. European Heart Journal, 2012, 33, 1049-1057. | 1.0 | 19 |
| 640 | The contraceptive revolution: focused efforts are still needed. Lancet, The, 2013, 381, 1604-1606. | 6.3 | 19 |
| 641 | Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). PLoS ONE, 2015, 10, e0133970. | 1.1 | 19 |
| 642 | Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease. American Heart Journal, 2016, 178, 28-36. | 1.2 | 19 |
| 643 | Independent academic Data Monitoring Committees for clinical trials in cardiovascular and cardiometabolic diseases. European Journal of Heart Failure, 2017, 19, 449-456. | 2.9 | 19 |
| 644 | Pathophysiology of exercise intolerance in chronic diseases: the role of diminished cardiac performance in mitochondrial and heart failure patients. Open Heart, 2017, 4, e000632. | 0.9 | 19 |
| 645 | Long term trends in behaviour to protect against adverse reproductive and sexual health outcomes among young single African women. Reproductive Health, 2018, 15, 136. | 1.2 | 19 |
| 646 | Prevalence and Incidence of Atrial Fibrillation in Ambulatory Patients With Heart Failure. American Journal of Cardiology, 2019, 124, 1554-1560. | 0.7 | 19 |
| 647 | Added value of frailty and social support in predicting risk of 30-day unplanned re-admission or death for patients with heart failure: An analysis from OPERA-HF. International Journal of Cardiology, 2019, 278, 167-172. | 0.8 | 19 |
| 648 | Myocardial remodelling after withdrawing therapy for heart failure in patients with recovered dilated cardiomyopathy: insights from <scp>TREDâ€HF</scp> . European Journal of Heart Failure, 2021, 23, 293-301. | 2.9 | 19 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 649 | Is acute heart failure a distinctive disorder? An analysis from BIOSTATâ€CHF. European Journal of Heart Failure, 2021, 23, 43-57. | 2.9 | 19 |
| 650 | Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 2021, 23, 754-764. | 2.9 | 19 |
| 651 | Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial. Circulation: Heart Failure, 2021, 14, CIRCHEARTFAILURE121008597. | 1.6 | 19 |
| 652 | Equity, Security and Fertility: A Reaction to Thomas. Population Studies, 1993, 47, 345-352. | 1.1 | 18 |
| 653 | Clinical trials update from the European Society of Cardiology: SENIORS, ACES, PROVE-IT, ACTION, and the HF-ACTION trial. European Journal of Heart Failure, 2004, 6, 787-791. | 2.9 | 18 |
| 654 | The prognostic value of individual NT-proBNP values in chronic heart failure does not change with advancing age. Heart, 2009, 95, 825-829. | 1.2 | 18 |
| 655 | Experiences of air travel in patients with chronic heart failure. International Journal of Cardiology, 2012, 158, 66-70. | 0.8 | 18 |
| 656 | Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). European Heart Journal, 2014, 35, 3426-3433. | 1.0 | 18 |
| 657 | An Assessment of Childbearing Preferences in Northern Malawi. Studies in Family Planning, 2015, 46, 161-176. | 1.0 | 18 |
| 658 | Postpartum and Postâ€Abortion Contraception: From Research to Programs. Studies in Family Planning, 2015, 46, 343-353. | 1.0 | 18 |
| 659 | A user-centred home monitoring and self-management system for patients with heart failure: a multicentre cohort study. European Heart Journal Quality of Care & Clinical Outcomes, 2015, 1, 66-71. | 1.8 | 18 |
| 660 | Improving the Measurement of Fertility Regulation Practices: Findings from Qualitative Research in Ghana. International Perspectives on Sexual and Reproductive Health, 2017, 43, 111. | 3.8 | 18 |
| 661 | Epidemiology and long-term outcome in outpatients with chronic heart failure in Northwestern Europe. Heart, 2019, 105, 1252-1259. | 1.2 | 18 |
| 662 | Percutaneous haemodynamic and renal support in patients presenting with decompensated heart failure: A multi-centre efficacy study using the Reitan Catheter Pump (RCP). International Journal of Cardiology, 2019, 275, 53-58. | 0.8 | 18 |
| 663 | Chronic Obstructive Pulmonary Disease and Heart Failure. Heart Failure Clinics, 2020, 16, 33-44. | 1.0 | 18 |
| 664 | Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the <scp>REPORTâ€HF</scp> registry. European Journal of Heart Failure, 2022, 24, 645-652. | 2.9 | 18 |
| 665 | Heart failure update. European Journal of Heart Failure, 1999, 1, 301-302. | 2.9 | 17 |
| 666 | Defibrillators—a shocking therapy for cardiomyopathy?. Nature Reviews Cardiology, 2010, 7, 69-70. | 6.1 | 17 |

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 667 | Prevalence of scarred and dysfunctional myocardium in patients with heart failure of ischaemic origin: A cardiovascular magnetic resonance study. Journal of Cardiovascular Magnetic Resonance, 2011, 13, 53. | 1.6 | 17 |
| 668 | Variation in hospital performance for heart failure management in the National Heart Failure Audit for England and Wales. Heart, 2017, 103, 55-62. | 1.2 | 17 |
| 669 | Plasma Neutrophil Gelatinase-Associated Lipocalin and Predicting Clinically Relevant Worsening Renal Function in Acute Heart Failure. International Journal of Molecular Sciences, 2017, 18, 1470. | 1.8 | 17 |
| 670 | Acute heart failure: lessons learned, roads ahead. European Journal of Heart Failure, 2018, 20, 842-850. | 2.9 | 17 |
| 671 | Childbearing desires and behaviour: a prospective assessment in Nairobi slums. BMC Pregnancy and Childbirth, 2019, 19, 100. | 0.9 | 17 |
| 672 | Effects of a Novel Nitroxyl Donor in Acute HeartÂFailure. JACC: Heart Failure, 2021, 9, 146-157. | 1.9 | 17 |
| 673 | Biomarkers as predictors of recurrence of atrial fibrillation post ablation: an updated and expanded systematic review and meta-analysis. Clinical Research in Cardiology, 2022, 111, 680-691. | 1.5 | 17 |
| 674 | High- versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial. American Journal of Managed Care, 2003, 9, 417-24. | 0.8 | 17 |
| 675 | Survival trends, coronary event rates, and the MONICA project. Lancet, The, 1999, 354, 862. | 6.3 | 16 |
| 676 | Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study. European Journal of Heart Failure, 1999, 1, 73-79. | 2.9 | 16 |
| 677 | Clinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEM. European Journal of Heart Failure, 2003, 5, 697-704. | 2.9 | 16 |
| 678 | Multi-chamber pacing: a perfect solution for cardiac mechanical dyssynchrony?. European Heart Journal, 2003, 24, 384-390. | 1.0 | 16 |
| 679 | Diastolic Heart Failure: A Difficult Problem in the Elderly. The American Journal of Geriatric Cardiology, 2004, 13, 16-21. | 0.7 | 16 |
| 680 | Cardiorespiratory Requirements of the 6-Min Walk Test in Older Patients with Left Ventricular Systolic Dysfunction and No Major Structural Heart Disease. International Journal of Sports Medicine, 2007, 28, 678-684. | 0.8 | 16 |
| 681 | Ruling out heart failure in primary-care: The cost-benefit of pre-screening using NT-proBNP and QRS width. International Journal of Cardiology, 2008, 130, 426-437. | 0.8 | 16 |
| 682 | Current state of knowledge and experts' perspective on the subcutaneous implantable cardioverter-defibrillator. Journal of Interventional Cardiac Electrophysiology, 2009, 25, 83-88. | 0.6 | 16 |
| 683 | Derivation and validation of a simple clinical risk-model in heart failure based on 6Âminute walk test performance and NT-proBNP status – Do we need specificity for sex and beta-blockers?. International Journal of Cardiology, 2011, 147, 74-78. | 0.8 | 16 |
| 684 | A comparative study of missing value imputation with multiclass classification for clinical heart failure data. , 2012, , . | | 16 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 685 | Does cirrhotic cardiomyopathy exist? 50Âyears of uncertainty. Clinical Research in Cardiology, 2013, 102, 859-864. | 1.5 | 16 |
| 686 | The C-CURE Randomized Clinical Trial (Cardiopoietic stem Cell therapy in heart failURE). Journal of the American College of Cardiology, 2013, 62, 2453. | 1.2 | 16 |
| 687 | Coronary angiography in worsening heart failure: determinants, findings and prognostic implications. Heart, 2018, 104, 606-613. | 1.2 | 16 |
| 688 | Trajectories of Changes in Renal Function in Patients with Acute Heart Failure. Journal of Cardiac Failure, 2019, 25, 866-874. | 0.7 | 16 |
| 689 | Biomarkerâ€based assessment of collagen crossâ€linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the <scp>HOMAGE</scp> clinical trial. European Journal of Heart Failure, 2022, 24, 321-331. | 2.9 | 16 |
| 690 | Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the <scp>SilHF</scp> study): a randomized placeboâ€controlled multicentre trial. European Journal of Heart Failure, 2022, 24, 1239-1248. | 2.9 | 16 |
| 691 | Combination of verapamil and beta blockers in systemic hypertension. American Journal of Cardiology, 1986, 57, D80-D82. | 0.7 | 15 |
| 692 | Nonâ€invasive Evaluation of Cardiac Function in Young Patients with Type 1 Diabetes. Diabetic Medicine, 1989, 6, 677-681. | 1.2 | 15 |
| 693 | Carvedilol for Heart Failure: Clinical Trials in Progress. Heart Failure Reviews, 1999, 4, 89-96. | 1.7 | 15 |
| 694 | A method to reduce loss to follow-up in clinical trials: informed, withdrawal of consent. European Journal of Heart Failure, 2004, 6, 1-2. | 2.9 | 15 |
| 695 | Poor Relationship Between Exercise Capacity and Spirometric Measurements in Patients With More Symptomatic Heart Failure. Journal of Cardiac Failure, 2005, 11, 619-623. | 0.7 | 15 |
| 696 | Activation of sphingosine-1-phosphate signalling as a potential underlying mechanism of the pleiotropic effects of statin therapy. Critical Reviews in Clinical Laboratory Sciences, 2013, 50, 79-89. | 2.7 | 15 |
| 697 | Heart failure with preserved ejection fraction. Clinical Medicine, 2014, 14, s22-s28. | 0.8 | 15 |
| 698 | The in vitro stability of novel cardiovascular and sepsis biomarkers at ambient temperature. Clinical Chemistry and Laboratory Medicine, 2014, 52, 911-8. | 1.4 | 15 |
| 699 | Prevention or Procrastination for HeartÂFailure?. Journal of the American College of Cardiology, 2019, 73, 2398-2400. | 1.2 | 15 |
| 700 | Mode of presentation and mortality amongst patients hospitalized with heart failure? A report from the First Euro Heart Failure Survey. Clinical Research in Cardiology, 2019, 108, 510-519. | 1.5 | 15 |
| 701 | Cardiovascular and nonâ€cardiovascular death distinction: the utility of troponin beyond Nâ€terminal proâ€Bâ€type natriuretic peptide. Findings from the BIOSTATâ€CHF study. European Journal of Heart Failure, 2020, 22, 81-89. | 2.9 | 15 |
| 702 | The value of spot urinary creatinine as a marker of muscle wasting in patients with newâ€onset or worsening heart failure. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 555-567. | 2.9 | 15 |

| # | Article | IF | CITATIONS |
|-----|---|-----------------------|------------------------|
| 703 | Nonâ€adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatographyâ€ŧandem mass spectrometry (results of a prospective) Tj ETQq1 1 | 0.78431 49 gBT | - /Ove rlock 10 |
| 704 | N-terminal brain natriuretic peptide as a screening tool for heart failure in the pacemaker population. European Heart Journal, 2006, 27, 447-453. | 1.0 | 14 |
| 705 | Design and Rationale of the URGENT Dyspnea Study: An International, Multicenter, Prospective Study. American Journal of Therapeutics, 2008, 15, 299-303. | 0.5 | 14 |
| 706 | The Atrial Fibrillation Paradox of Heart Failure. Congestive Heart Failure, 2010, 16, 3-9. | 2.0 | 14 |
| 707 | Calcium supplements in people with osteoporosis. BMJ: British Medical Journal, 2010, 341, c3856-c3856. | 2.4 | 14 |
| 708 | Case Selection for Cardiac Resynchronization in Atrial Fibrillation. Heart Failure Clinics, 2013, 9, 461-474. | 1.0 | 14 |
| 709 | Precision Medicine for Cardiac Resynchronization. Circulation: Heart Failure, 2017, 10, . | 1.6 | 14 |
| 710 | Natriuretic Peptide-Based Inclusion Criteria in a HeartÂFailure Clinical Trial. JACC: Heart Failure, 2020, 8, 359-368. | 1.9 | 14 |
| 711 | Clobal Differences in Burden and Treatment of Ischemic Heart Disease in Acute HeartÂFailure. JACC: Heart Failure, 2021, 9, 349-359. | 1.9 | 14 |
| 712 | Reply to the letter regarding the article â€~Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure'. European Journal of Heart Failure, 2021, 23, 1800-1801. | 2.9 | 14 |
| 713 | Heart Failure due to Ischaemic Heart Disease: Epidemiology, Pathophysiology and Progression. Journal of Cardiovascular Pharmacology, 1999, 33, S17-S29. | 0.8 | 14 |
| 714 | The prevalence and clinical associations of ultrasound measures of congestion in patients at risk of developing heart failure. European Journal of Heart Failure, 2021, 23, 1831-1840. | 2.9 | 14 |
| 715 | Osteoporosis and Its Association With Cardiovascular Disease, Respiratory Disease, and Cancer: Findings From the UK Biobank Prospective Cohort Study. Mayo Clinic Proceedings, 2022, 97, 110-121. | 1.4 | 14 |
| 716 | Cost-effectiveness of transcatheter edge-to-edge repair in secondary mitral regurgitation. Heart, 2022, , heartjnl-2021-320005. | 1.2 | 14 |
| 717 | Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. European Heart Journal, 2022, 43, 863-867. | 1.0 | 14 |
| 718 | Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction. Scientific Reports, 2022, 12, . | 1.6 | 14 |
| 719 | Sexual Risk Behavior in Urban Populations of Northeastern Africa. AIDS and Behavior, 2001, 5, 343-352. | 1.4 | 13 |
| 720 | Prevention of and medical therapy for atrial arrhythmias in heart failure. Heart Failure Reviews, 2002, 7, 267-283. | 1.7 | 13 |

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 721 | Clinical trials update from the Heart Failure Society of America: EMOTE, HERB-CHF, BEST genetic sub-study and RHYTHM-ICD. European Journal of Heart Failure, 2004, 6, 953-955. | 2.9 | 13 |
| 722 | Clinical trials update from Heart Rhythm 2007 and Heart Failure 2007: CARISMA, PREPARE, DAVID II, SAVEâ€PACE, PROTECT and AREAâ€IN HF. European Journal of Heart Failure, 2007, 9, 850-853. | 2.9 | 13 |
| 723 | Clinical trials update from European Society of Cardiology meeting 2008: TIMEâ€CHF, BACH, BEAUTIFUL, GISSIâ€HF, and HOMEâ€HF. European Journal of Heart Failure, 2008, 10, 1264-1267. | 2.9 | 13 |
| 724 | Cardiac output does not limit submaximal exercise capacity in patients with chronic heart failure. European Journal of Heart Failure, 2010, 12, 983-989. | 2.9 | 13 |
| 725 | Renal artery stenosis: an innocent bystander or an independent predictor of worse outcome in patients with chronic heart failure? A magnetic resonance imaging study. European Journal of Heart Failure, 2012, 14, 764-772. | 2.9 | 13 |
| 726 | Multidisciplinary Approach for Patients Hospitalized With Heart Failure. Revista Espanola De Cardiologia (English Ed), 2015, 68, 885-891. | 0.4 | 13 |
| 727 | Dynamic risk stratification using serial measurements of plasma concentrations of natriuretic peptides in patients with heart failure. International Journal of Cardiology, 2018, 269, 196-200. | 0.8 | 13 |
| 728 | Characteristics and outcome of acute heart failure patients according to the severity of peripheral oedema. International Journal of Cardiology, 2019, 285, 40-46. | 0.8 | 13 |
| 729 | Plasma <scp>D</scp> â€dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the <scp>COMMANDERâ€HF</scp> trial. European Journal of Heart Failure, 2021, 23, 648-656. | 2.9 | 13 |
| 730 | Future research prioritization in cardiac resynchronization therapy. American Heart Journal, 2020, 223, 48-58. | 1.2 | 13 |
| 731 | Haemodynamic effects of the nitroxyl donor cimlanod (<scp>BMS</scp> â€986231) in chronic heart failure: a randomized trial. European Journal of Heart Failure, 2021, 23, 1147-1155. | 2.9 | 13 |
| 732 | To master heart failure, first master congestion. Lancet, The, 2021, 398, 935-936. | 6.3 | 13 |
| 733 | Angiography and the aetiology of heart failure Postgraduate Medical Journal, 1995, 71, 480-482. | 0.9 | 12 |
| 734 | ACE inhibitors in heart failure. What dose?. Postgraduate Medical Journal, 1995, 71, 65-66. | 0.9 | 12 |
| 735 | Population growth in the 21 st century: Cause for crisis or celebration?1. Tropical Medicine and International Health, 1996, 1, 15-26. | 1.0 | 12 |
| 736 | Update of ELITE-II, BEST, CHAMP, and IMPRESS clinical trials in heart failure. European Journal of Heart Failure, 2000, 2, 107-112. | 2.9 | 12 |
| 737 | Prevalence and inter-relationship of different Doppler measures of dyssynchrony in patients with heart failure and prolonged QRS: a report from CARE-HF. Cardiovascular Ultrasound, 2009, 7, 1. | 0.5 | 12 |
| 738 | Acute heart failure: focusing on acute cardiogenic pulmonary oedema. Clinical Medicine, 2010, 10, 59-64. | 0.8 | 12 |

| # | Article | IF | CITATIONS |
|-----|---|----------|----------------------|
| 739 | Revascularization for patients with heart failure. Inconsistencies between theory and practice. European Journal of Heart Failure, 2011, 13, 694-697. | 2.9 | 12 |
| 740 | Heart failure—does it matter whether LVEF is reduced?. Lancet, The, 2012, 380, 1363-1365. | 6.3 | 12 |
| 741 | The relationship of QRS morphology with cardiac structure and function in patients with heart failure. Clinical Research in Cardiology, 2015, 104, 935-945. | 1.5 | 12 |
| 742 | Outcome of hospitalised heart failure in Japan and the United Kingdom stratified by plasma N-terminal pro-B-type natriuretic peptide. Clinical Research in Cardiology, 2018, 107, 1103-1110. | 1.5 | 12 |
| 743 | Burden of medical coâ€morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy. European Journal of Heart Failure, 2019, 21, 373-381. | 2.9 | 12 |
| 744 | Heart failure etiologies and clinical factors precipitating for worsening heart failure: Findings from BIOSTAT-CHF. European Journal of Internal Medicine, 2020, 71, 62-69. | 1.0 | 12 |
| 745 | Serum potassium and outcomes in heart failure with preserved ejection fraction: a postâ€hoc analysis of the <scp>PARAGONâ€HF</scp> trial. European Journal of Heart Failure, 2021, 23, 776-784. | 2.9 | 12 |
| 746 | Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart). European Heart Journal, 2022, 43, 2185-2195. | 1.0 | 12 |
| 747 | Quality of life assessed six months after hospitalisation for acute heart failure: An analysis from <scp>REPORTâ€HF</scp> (International Registry to assess <scp>mEdical</scp> Practice with) Tj ETQq1 1 0.784 Failure. 2022 | 314 rgBT | Overlock 1° |
| 748 | Bronchial Hyperresponsiveness in Heart Failure. New England Journal of Medicine, 1993, 328, 1424-1425. | 13.9 | 11 |
| 749 | AREA VARIATIONS IN USE OF MODERN CONTRACEPTION IN RURAL BANGLADESH: A MULTILEVEL ANALYSIS. Journal of Biosocial Science, 1999, 31, 327-341. | 0.5 | 11 |
| 750 | Clinical trials update from the American Heart Association meeting: PROSPER, DIAL, home care monitoring trials, immune modulation therapy, COMPANION and anaemia in heart failure. European Journal of Heart Failure, 2003, 5, 95-99. | 2.9 | 11 |
| 751 | A Description of the Clinical Characteristics at Baseline of Patients Recruited into the Carvedilol or Metoprolol European Trial (COMET). Cardiovascular Drugs and Therapy, 2004, 18, 139-152. | 1.3 | 11 |
| 752 | Chronic aspirin therapy for the prevention of cardiovascular events: a waste of time, or worse?. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 234-235. | 3.3 | 11 |
| 753 | Combining the ventilatory response to exercise and peak oxygen consumption is no better than peak oxygen consumption alone in predicting mortality in chronic heart failure. European Journal of Heart Failure, 2008, 10, 85-88. | 2.9 | 11 |
| 754 | Yearsâ€neededâ€ŧoâ€ŧreat to add 1 year of life: a new metric to estimate treatment effects in randomized trials. European Journal of Heart Failure, 2009, 11, 256-263. | 2.9 | 11 |
| 755 | Abordaje multidisciplinario en pacientes hospitalizados por insuficiencia cardiaca. Revista Espanola De Cardiologia, 2015, 68, 885-891. | 0.6 | 11 |
| 756 | Taxonomy of segmental myocardial systolic dysfunction. European Heart Journal, 2017, 38, ehw140. | 1.0 | 11 |

| # | Article | IF | CITATIONS |
|-----|--|------|-----------|
| 757 | Acute heart failure in the young: Clinical characteristics and biomarker profiles. International Journal of Cardiology, 2016, 221, 1067-1072. | 0.8 | 11 |
| 758 | Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure. Circulation: Heart Failure, 2017, 10, . | 1.6 | 11 |
| 759 | Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 82-92. | 1.4 | 11 |
| 760 | The shocking lack of evidence for implantable cardioverter defibrillators for heart failure; with or without cardiac resynchronization. European Heart Journal, 2019, 40, 2128-2130. | 1.0 | 11 |
| 761 | Factors influencing satisfaction with oral contraceptive pills and injectables among past users in Kenya. Journal of Biosocial Science, 2019, 51, 491-504. | 0.5 | 11 |
| 762 | The complex relationship between contraception and abortion. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2020, 62, 90-100. | 1.4 | 11 |
| 763 | What do patients with heart failure die from? A single assassin or a conspiracy?. European Journal of Heart Failure, 2020, 22, 26-28. | 2.9 | 11 |
| 764 | The year in cardiology: heart failure. European Heart Journal, 2020, 41, 1232-1248. | 1.0 | 11 |
| 765 | Men's needs and women's fears: gender-related power dynamics in contraceptive use and coping with consequences in a rural setting in Kenya. Culture, Health and Sexuality, 2020, 23, 1-15. | 1.0 | 11 |
| 766 | Safety and Efficacy of Intravenous Ferric Derisomaltose Compared to Iron Sucrose for Iron Deficiency Anemia in Patients with Chronic Kidney Disease With and Without Heart Failure. American Journal of Cardiology, 2021, 152, 138-145. | 0.7 | 11 |
| 767 | Association between upâ€ŧitration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum. European Journal of Heart Failure, 2021, 23, 1170-1181. | 2.9 | 11 |
| 768 | Identification of sexâ€specific biomarkers predicting newâ€onset heart failure. ESC Heart Failure, 2021, 8, 3512-3520. | 1.4 | 11 |
| 769 | A novel treatment for heart failure targets myocardial fibrosis. Nature Medicine, 2021, 27, 1343-1344. | 15.2 | 11 |
| 770 | The genomics of heart failure: design and rationale of the HERMES consortium. ESC Heart Failure, 2021, 8, 5531-5541. | 1.4 | 11 |
| 771 | Hospitalization for Heart Failure in the United States, UK, Taiwan, and Japan: An International Comparison of Administrative Health Records on 413,385 Individual Patients. Journal of Cardiac Failure, 2022, 28, 353-366. | 0.7 | 11 |
| 772 | The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an <scp>individual patient data metaâ€analysis</scp> of <scp>COMPANION</scp> and <scp>CAREâ€HF</scp> . European Journal of Heart Failure, 2022, 24, 1080-1090. | 2.9 | 11 |
| 773 | Association of gamma-glutamyltransferase levels with total mortality, liver-related and cardiovascular outcomes: A prospective cohort study in the UK Biobank. EClinicalMedicine, 2022, 48, 101435. | 3.2 | 11 |
| 774 | Angiotensin-converting enzyme inhibitors, left ventricular dysfunction, and early heart failure. American Journal of Cardiology, 1992, 70, 55-61. | 0.7 | 10 |

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 775 | Inhibition of the renin-angiotensin-aldosterone system in heart failure: new insights from basic clinical research. Current Opinion in Cardiology, 1996, 11, 252-262. | 0.8 | 10 |
| 776 | Depression and heart failure — not yet a target for therapy?. European Heart Journal, 1999, 20, 1529-1531. | 1.0 | 10 |
| 777 | Politics and fertility: a new approach to population policy analysis. Population Research and Policy Review, 2000, 19, 1-28. | 1.0 | 10 |
| 778 | Validation of an echocardiographic wall motion index in heart failure due to ischaemic heart disease. European Journal of Heart Failure, 2001, 3, 731-737. | 2.9 | 10 |
| 779 | Anemia and Chronic Heart Failure. Circulation, 2005, 112, 1681-1683. | 1.6 | 10 |
| 780 | The Trans-European Network ??? Home-Care Management System (TEN???HMS) Study: An Investigation of the Effect of Telemedicine on Outcomes in Europe. Disease Management and Health Outcomes, 2006, 14, 23???28. | 0.3 | 10 |
| 781 | Pharmacokinetic and Pharmacodynamic Characteristics of β-Blockers: When Differences May Matter. Journal of Cardiac Failure, 2006, 12, 177-181. | 0.7 | 10 |
| 782 | Screening for left ventricular systolic dysfunction in highâ€risk patients in primaryâ€care: A costâ€benefit analysis. European Journal of Heart Failure, 2007, 9, 1186-1195. | 2.9 | 10 |
| 783 | Interpretation of Amino-Terminal Pro-Brain Natriuretic Peptide Levels in the HPS and the CORONA Study. Journal of the American College of Cardiology, 2008, 52, 1104-1105. | 1.2 | 10 |
| 784 | Clinical trials update from the European Society of Cardiology heart failure meeting 2009: CHANCE, B-Convinced, CHAT, CIBIS-ELD, and Signal-HF. European Journal of Heart Failure, 2009, 11, 802-805. | 2.9 | 10 |
| 785 | Questioning the predictive role of carotid intima–media thickness. Future Cardiology, 2011, 7, 651-656. | 0.5 | 10 |
| 786 | Handling missing values in data mining - A case study of heart failure dataset. , 2012, , . | | 10 |
| 787 | Impact of aspirin and statins on longâ€ŧerm survival in patients hospitalized with acute myocardial infarction complicated by heart failure: an analysis of 1706 patients. European Journal of Heart Failure, 2014, 16, 95-102. | 2.9 | 10 |
| 788 | Remote telemonitoring for patients with heart failure: might monitoring pulmonary artery pressure become routine?. Expert Review of Cardiovascular Therapy, 2014, 12, 1025-1033. | 0.6 | 10 |
| 789 | Unmet Need for Family Planning: Past Achievements and Remaining Challenges. Seminars in Reproductive Medicine, 2015, 33, 011-016. | 0.5 | 10 |
| 790 | If home telemonitoring reduces mortality in heart failure, is this just due to better guideline-based treatment?. Journal of Telemedicine and Telecare, 2015, 21, 331-339. | 1.4 | 10 |
| 791 | Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial. American Heart Journal, 2017, 190, 113-122. | 1.2 | 10 |
| 792 | Selecting Patients With Nonischemic Dilated Cardiomyopathy for ICDs. Journal of the American College of Cardiology, 2017, 70, 1228-1231. | 1.2 | 10 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 793 | Estimated peak functional capacity: an accurate method for assessing change in peak oxygen consumption after cardiac rehabilitation?. Clinical Physiology and Functional Imaging, 2018, 38, 681-688. | 0.5 | 10 |
| 794 | Mortality after admission for heart failure in the UK compared with Japan. Open Heart, 2018, 5, e000811. | 0.9 | 10 |
| 795 | Comparative effectiveness of loop diuretics on mortality in the treatment of patients with chronic heart failure – A multicenter propensity score matched analysis. International Journal of Cardiology, 2019, 289, 83-90. | 0.8 | 10 |
| 796 | Valuing health-related quality of life in heart failure: a systematic review of methods to derive quality-adjusted life years (QALYs) in trial-based cost–utility analyses. Heart Failure Reviews, 2019, 24, 549-563. | 1.7 | 10 |
| 797 | Engage In or Refrain From? A Qualitative Exploration of Premarital Sexual Relations Among Female College Students in Tehran. Journal of Sex Research, 2019, 56, 1009-1022. | 1.6 | 10 |
| 798 | Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation. Clinical Research in Cardiology, 2019, 108, 797-805. | 1.5 | 10 |
| 799 | Electrocardiographic characteristics in patients with heart failure and normal ejection fraction: A systematic review and metaâ€analysis. Annals of Noninvasive Electrocardiology, 2020, 25, e12710. | 0.5 | 10 |
| 800 | Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF. Cardiovascular Research, 2022, 118, 1964-1977. | 1.8 | 10 |
| 801 | Prognostic Significance of Nonischemic Myocardial Fibrosis in Patients WithÂNormal LV Volumes and Ejection-Fraction. JACC: Cardiovascular Imaging, 2021, 14, 2353-2365. | 2.3 | 10 |
| 802 | Serum and urinary biomarkers of collagen typeâ€l turnover predict prognosis in patients with heart failure. Clinical and Translational Medicine, 2021, 11, e267. | 1.7 | 10 |
| 803 | Protocol for an implementation study of an evidence-based home cardiac rehabilitation programme for people with heart failure and their caregivers in Scotland (SCOT:REACH-HF). BMJ Open, 2020, 10, e040771. | 0.8 | 10 |
| 804 | Urban Family Planning in Low- and Middle-Income Countries: A Critical Scoping Review. Frontiers in Global Women S Health, 2021, 2, 749636. | 1.1 | 10 |
| 805 | Aspirin use is associated with increased risk for incident heart failure: a patientâ€level pooled analysis. ESC Heart Failure, 2022, 9, 685-694. | 1.4 | 10 |
| 806 | Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: A systematic review and meta-analysis of randomised trials. Pharmacological Research, 2022, 176, 106053. | 3.1 | 10 |
| 807 | Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure. Clinical Research in Cardiology, 2022, 111, 912-923. | 1.5 | 10 |
| 808 | Distinct pathophysiological pathways in women and men with heart failure. European Journal of Heart Failure, 2022, 24, 1532-1544. | 2.9 | 10 |
| 809 | Optimising heart failure pharmacotherapy: the ideal combination. Heart, 1994, 72, S73-S79. | 1.2 | 9 |
| 810 | Therapeutic options and cost considerations in the treatment of ischemic heart disease. , 1998, 12, 225-232. | | 9 |

810 225-232.

| # | Article | IF | CITATIONS |
|-----|---|------|-----------|
| 811 | Are symptoms the most important target for therapy in chronic heart failure?. Progress in Cardiovascular Diseases, 1998, 41, 59-64. | 1.6 | 9 |
| 812 | Novel cardiac myosin activators for acute heart failure. Expert Opinion on Investigational Drugs, 2007, 16, 1541-1548. | 1.9 | 9 |
| 813 | Patients with heart failure who require an implantable defibrillator should have cardiac resynchronisation routinely. Heart, 2008, 94, 963-966. | 1.2 | 9 |
| 814 | Cardiac resynchronization therapy: dyssynchrony imaging from a heart failure perspective. Current Opinion in Cardiology, 2008, 23, 634-645. | 0.8 | 9 |
| 815 | An Entirely Subcutaneous Implantable Cardioverter–Defibrillator. New England Journal of Medicine, 2010, 363, 1577-1578. | 13.9 | 9 |
| 816 | Clinical trials update from the European Society of Cardiology Heart Failure meeting 2011: TEHAF, WHICH, CARVIVA, and atrial fibrillation in GISSIâ€HF and EMPHASISâ€HF. European Journal of Heart Failure, 2011, 13, 1147-1151. | 2.9 | 9 |
| 817 | Atherosclerotic disease of the abdominal aorta and its branches: prognostic implications in patients with heart failure. Heart Failure Reviews, 2012, 17, 229-239. | 1.7 | 9 |
| 818 | Role of Antithrombotic Agents in Heart Failure. Current Cardiology Reports, 2012, 14, 314-325. | 1.3 | 9 |
| 819 | Predictive power of late gadolinium enhancement for myocardial recovery in chronic ischaemic heart failure: a HEART subâ€study. ESC Heart Failure, 2014, 1, 146-153. | 1.4 | 9 |
| 820 | The Effect of Carvedilol on B-Type Natriuretic Peptide and Cardiac Function in Patients with Heart Failure and Persistent Atrial Fibrillation. Cardiology, 2015, 130, 153-158. | 0.6 | 9 |
| 821 | Effect of renal artery revascularization upon cardiac structure and function in atherosclerotic renal artery stenosis: cardiac magnetic resonance sub-study of the ASTRAL trial. Nephrology Dialysis Transplantation, 2016, 32, gfw107. | 0.4 | 9 |
| 822 | Methodâ€ s pecific Attributes that Influence Choice of Future Contraception Among Married Women in Nairobi's Informal Settlements. Studies in Family Planning, 2018, 49, 279-292. | 1.0 | 9 |
| 823 | Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure. Circulation: Heart Failure, 2020, 13, e007814. | 1.6 | 9 |
| 824 | Impaired Highâ€Ðensity Lipoprotein Function in Patients With Heart Failure. Journal of the American Heart Association, 2021, 10, e019123. | 1.6 | 9 |
| 825 | Cardiac Resynchronization Therapy in Heart Failure. Annals of Internal Medicine, 2005, 142, 305. | 2.0 | 9 |
| 826 | Sarcoid, amyloid and heart failure. International Journal of Cardiology, 1993, 41, 180-182. | 0.8 | 8 |
| 827 | ACE Inhibitors for â€~Diastolic' Heart Failure? Reasons not to jump to premature conclusions about the efficacy of ACE inhibitors among older patients with heart failure. European Journal of Heart Failure, 2001, 3, 637-639. | 2.9 | 8 |
| 828 | What is the optimal medical management of ischaemic heart failure?. British Medical Bulletin, 2001, 59, 135-158. | 2.7 | 8 |

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 829 | How do you measure exercise capacity in chronic heart failure?. European Heart Journal, 2001, 22, 627-628. | 1.0 | 8 |
| 830 | Diagnosis and management of patients with heart failure in England. Clinical Medicine, 2008, 8, 264-266. | 0.8 | 8 |
| 831 | Cost-effectiveness of enhanced external counterpulsation (EECP) for the treatment of stable angina in the United Kingdom. International Journal of Technology Assessment in Health Care, 2010, 26, 175-182. | 0.2 | 8 |
| 832 | Abnormalities of the Ventilatory Equivalent for Carbon Dioxide in Patients with Chronic Heart Failure. Pulmonary Medicine, 2012, 2012, 1-6. | 0.5 | 8 |
| 833 | Is the diagnostic coding position of acute heart failure related to mortality? A report from the Euro Heart Failure Surveyâ€1. European Journal of Heart Failure, 2016, 18, 556-563. | 2.9 | 8 |
| 834 | Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA). Biomarkers, 2017, 22, 261-267. | 0.9 | 8 |
| 835 | What can we learn from SOCRATES: more questions than answers?. European Heart Journal, 2017, 38, 1128-1131. | 1.0 | 8 |
| 836 | Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial. Cardiovascular Drugs and Therapy, 2017, 31, 281-293. | 1.3 | 8 |
| 837 | Differences in biomarkers and molecular pathways according to age for patients with HFrEF. Cardiovascular Research, 2021, 117, 2228-2236. | 1.8 | 8 |
| 838 | Eplerenone prevents an increase in serum carboxyâ€ŧerminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and/or heart failure. European Journal of Heart Failure, 2020, 22, 901-903. | 2.9 | 8 |
| 839 | Pregnancy intention data completeness, quality and utility in population-based surveys: EN-INDEPTH study. Population Health Metrics, 2021, 19, 6. | 1.3 | 8 |
| 840 | Prognostic value of the chest X-ray in patients hospitalised for heart failure. Clinical Research in Cardiology, 2021, 110, 1743-1756. | 1.5 | 8 |
| 841 | Method-specific beliefs and subsequent contraceptive method choice: Results from a longitudinal study in urban and rural Kenya. PLoS ONE, 2021, 16, e0252977. | 1.1 | 8 |
| 842 | β-Blockers for Chronic Heart Failure: From Prejudice to Enlightenment. Journal of Cardiovascular Pharmacology, 1998, 32, S52-S60. | 0.8 | 8 |
| 843 | Metabolic gas kinetics depend upon the level of exercise performed. European Journal of Heart Failure, 2005, 7, 991-996. | 2.9 | 7 |
| 844 | Relation between severity of left ventricular systolic dysfunction and repolarisation abnormalities on the surface ECG: a report from the Euro heart failure survey. Heart, 2006, 92, 255-256. | 1.2 | 7 |
| 845 | Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or Von Willebrand factor in chronic heart failure - a COMET substudy. Thrombosis Research, 2010, 125, e46-e50. | 0.8 | 7 |
| 846 | Standardized Reporting Criteria for Studies Evaluating Suspected Acute Heart Failure Syndromes in the Emergency Department. Journal of the American College of Cardiology, 2012, 60, 822-832. | 1.2 | 7 |

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 847 | Xanthine Oxidase Inhibition for the Treatment of Cardiovascular Disease: A Systematic Review and Metaâ€Analysis. Cardiovascular Therapeutics, 2014, 32, 57-58. | 1.1 | 7 |
| 848 | Development of a Human Model for the Study of Effects of Hypoxia, Exercise, and Sildenafil on Cardiac and Vascular Function in Chronic Heart Failure. Journal of Cardiovascular Pharmacology, 2015, 66, 229-238. | 0.8 | 7 |
| 849 | Regional circulatory distribution of novel cardiac bio-markers and their relationships with haemodynamic measurements. International Journal of Cardiology, 2016, 210, 149-155. | 0.8 | 7 |
| 850 | Time to Take the Failure OutÂofÂHeartÂFailure. JACC: Heart Failure, 2017, 5, 538-540. | 1.9 | 7 |
| 851 | Does rhythm matter in acute heart failure? An insight from the British Society for Heart Failure National Audit. Clinical Research in Cardiology, 2019, 108, 1276-1286. | 1.5 | 7 |
| 852 | Implications of serial measurements of natriuretic peptides in heart failure: insights from <scp>BIOSTATâ€CHF</scp> . European Journal of Heart Failure, 2020, 22, 1486-1490. | 2.9 | 7 |
| 853 | Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study. Clinical Research in Cardiology, 2020, 109, 967-977. | 1.5 | 7 |
| 854 | Temporal trends in heart failure medication prescription in a population-based cohort study. BMJ Open, 2021, 11, e043290. | 0.8 | 7 |
| 855 | Effects of parental stature on child stunting in India. Journal of Biosocial Science, 2022, 54, 605-616. | 0.5 | 7 |
| 856 | The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. Journal of Cardiac Failure, 2021, 27, 808-811. | 0.7 | 7 |
| 857 | Heart Rate as a Marker of Relapse During Withdrawal of Therapy in Recovered Dilated Cardiomyopathy. JACC: Heart Failure, 2021, 9, 509-517. | 1.9 | 7 |
| 858 | Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial. Cardiovascular Diabetology, 2021, 20, 163. | 2.7 | 7 |
| 859 | Design and Usage of the HeartCycle Education and Coaching Program for Patients With Heart Failure. JMIR Research Protocols, 2014, 3, e72. | 0.5 | 7 |
| 860 | Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the <scp>HOMAGE</scp> trial. European Journal of Heart Failure, 2022, 24, 771-778. | 2.9 | 7 |
| 861 | Predicting mortality after hospitalisation for COPD using electronic health records. Pharmacological Research, 2022, 179, 106199. | 3.1 | 7 |
| 862 | Clinical implications of low estimated protein intake in patients with heart failure. Journal of Cachexia, Sarcopenia and Muscle, 2022, , . | 2.9 | 7 |
| 863 | Chronic Obstructive Pulmonary Disease and Heart Failure. Cardiology Clinics, 2022, 40, 171-182. | 0.9 | 7 |
| 864 | Implantable left ventricular assist systems (LVAS): Recent results. A report from a series of meetings sponsored by the Study Group on Advanced Heart Failure of the Working Group on Heart Failure. European Journal of Heart Failure, 2000, 2, 13-18. | 2.9 | 6 |

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 865 | β-Blockers, Exercise, and Ventilation in Chronic Heart Failure. Journal of Cardiac Failure, 2005, 11, 340-342. | 0.7 | 6 |
| 866 | The effect of ventricular pacing on measurements of left ventricular function: A comparison between echocardiographic methods and with radionuclide ventriculographyâ^†. European Journal of Echocardiography, 2006, 7, 284-292. | 2.3 | 6 |
| 867 | Should Patients who have Persistent Severe Symptoms Receive a Left Ventricular Assist Device or Cardiac Resynchronization Therapy as the Next Step?. Heart Failure Clinics, 2007, 3, 267-273. | 1.0 | 6 |
| 868 | Long-term aspirin for coronary artery disease: are we being deceived by a biased presentation of the evidence?. Future Cardiology, 2010, 6, 141-146. | 0.5 | 6 |
| 869 | Clinical trials update from the European Society of Cardiology Meeting 2011: ARISTOTLE, SMARTâ€AV: QLV substudy, SHIFT: echocardiography and quality of life substudies, European CRT Survey, and Basic Science Update. European Journal of Heart Failure, 2011, 13, 1376-1380. | 2.9 | 6 |
| 870 | Clinical trials update from the American College of Cardiology Meeting 2011: STICH, NorthStar, TARGET, and EVEREST II. European Journal of Heart Failure, 2011, 13, 805-808. | 2.9 | 6 |
| 871 | Medical Management of Stable Coronary Atherosclerosis. Current Atherosclerosis Reports, 2013, 15, 313. | 2.0 | 6 |
| 872 | Diabetes, aliskiren, and heart failure: let's bring ASTRONAUT down to earth. European Heart Journal, 2013, 34, 3097-3099. | 1.0 | 6 |
| 873 | The utility of novel non-invasive technologies for remote hemodynamic monitoring in chronic heart failure. Expert Review of Cardiovascular Therapy, 2014, 12, 923-928. | 0.6 | 6 |
| 874 | Update on management of heart failure with preserved ejection fraction. Current Opinion in Cardiology, 2015, 30, 173-178. | 0.8 | 6 |
| 875 | Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure — Post-hoc analysis of the PROTECT trial. International Journal of Cardiology, 2016, 223, 967-975. | 0.8 | 6 |
| 876 | Does aspirin detract from the benefits of mineralocorticoid receptor antagonists in patients with heart failure and a reduced left ventricular ejection fraction? Probably!. European Journal of Heart Failure, 2017, 19, 1086-1088. | 2.9 | 6 |
| 877 | Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure. Clinical Proteomics, 2018, 15, 35. | 1.1 | 6 |
| 878 | Telehealth: delivering high-quality care for heart failure. Lancet, The, 2018, 392, 990-991. | 6.3 | 6 |
| 879 | Myocardial Dysfunction and Coronary Artery Disease as Therapeutic Targets in Heart Failure. Circulation, 2019, 140, 538-541. | 1.6 | 6 |
| 880 | First in Human VisONE Heart Failure Study: Asymptomatic Diaphragmatic Stimulation for Chronic Heart Failure: One Month Results. Journal of Cardiac Failure, 2019, 25, S183. | 0.7 | 6 |
| 881 | Impact of Geographic Region on the COMMANDER-HF Trial. JACC: Heart Failure, 2021, 9, 201-211. | 1.9 | 6 |
| 882 | New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trial. Clinical Research in Cardiology, 2022, 111, 50-59. | 1.5 | 6 |

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 883 | Stem cell therapy for dilated cardiomyopathy. The Cochrane Library, 2021, 2021, CD013433. | 1.5 | 6 |
| 884 | A comparison of nonâ€invasive methods of measuring body composition in patients with heart failure: a report from SICAâ€HF. ESC Heart Failure, 2021, 8, 3929-3934. | 1.4 | 6 |
| 885 | Whole blood transcriptomic profiling identifies molecular pathways related to cardiovascular mortality in heart failure. European Journal of Heart Failure, 2022, 24, 1009-1019. | 2.9 | 6 |
| 886 | Shortened duration of post-ischemic hyperemic blood flow in the forearm of patients with heart failure. American Journal of Cardiology, 1996, 77, 300-302. | 0.7 | 5 |
| 887 | Adverse event with first-dose perindopril in congestive heart failure. Lancet, The, 1997, 350, 520-521. | 6.3 | 5 |
| 888 | Update of recent clinical trials in heart failure and myocardial infarction. European Journal of Heart Failure, 1999, 1, 109-115. | 2.9 | 5 |
| 889 | Taking heart failure seriously. BMJ: British Medical Journal, 2000, 321, 1095-1096. | 2.4 | 5 |
| 890 | Betaâ€blockers in the treatment of cardiovascular disease. The Prescriber, 2008, 19, 31-39. | 0.1 | 5 |
| 891 | Body mass index is related to the perception of exertional breathlessness in patients presenting with dyspnoea of unknown origin. International Journal of Cardiology, 2012, 157, 300-303. | 0.8 | 5 |
| 892 | Use of Carotid Intima-Media Thickness Regression to Guide Therapy and Management of Cardiac Risks. Current Treatment Options in Cardiovascular Medicine, 2012, 14, 50-56. | 0.4 | 5 |
| 893 | Why Does CRT Reduce the Risk of Arrhythmias?. JACC: Cardiovascular Imaging, 2013, 6, 445-447. | 2.3 | 5 |
| 894 | Definitions of Outcome, Response and Effect in Imaging Research to Avoid Confusion. JACC: Cardiovascular Imaging, 2014, 7, 104-106. | 2.3 | 5 |
| 895 | Aspirin for Heart Failure. Circulation: Heart Failure, 2014, 7, 237-238. | 1.6 | 5 |
| 896 | Does Speckle Tracking Really Improve Diagnosis and Risk Stratification in Patients With HF With Normal EF?. Journal of the American College of Cardiology, 2014, 64, 1535. | 1.2 | 5 |
| 897 | Lipid-Modifying Treatments for Heart Failure. Heart Failure Clinics, 2014, 10, 621-634. | 1.0 | 5 |
| 898 | Statins attenuate but do not eliminate the reverse epidemiology of total serum cholesterol in patients with non-ischemic chronic heart failure. International Journal of Cardiology, 2017, 238, 97-104. | 0.8 | 5 |
| 899 | Physicians Addicted to Prescribing Aspirin-a Disorder Of Cardiologists (PAPA-DOC) Syndrome. JACC: Heart Failure, 2018, 6, 168-171. | 1.9 | 5 |
| 900 | Clinical and prognostic relationships of pulmonary artery to aorta diameter ratio in patients with heart failure: a cardiac magnetic resonance imaging study. Clinical Cardiology, 2018, 41, 20-27. | 0.7 | 5 |

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 901 | Mid-regional proatrial natriuretic peptide for predicting prognosis in hypertrophic cardiomyopathy. Heart, 2019, 106, heartjnl-2019-314826. | 1.2 | 5 |
| 902 | Sex differences in child health and healthcare: A reappraisal for India. Population Studies, 2020, 74, 379-398. | 1.1 | 5 |
| 903 | Heart failure re-hospitalizations and subsequent fatal events in coronary artery disease: insights from COMMANDER-HF, EPHESUS, and EXAMINE. Clinical Research in Cardiology, 2021, 110, 1554-1563. | 1.5 | 5 |
| 904 | Is newborn survival influenced by place of delivery? A comparison of home, public sector and private sector deliveries in India. Journal of Biosocial Science, 2022, 54, 184-198. | 0.5 | 5 |
| 905 | Telomere length is independently associated with all-cause mortality in chronic heart failure. Heart, 2022, 108, 124-129. | 1.2 | 5 |
| 906 | Remote history of VTE is associated with severe COVIDâ€19 in middle and older age: UK Biobank cohort study. Journal of Thrombosis and Haemostasis, 2021, 19, 2533-2538. | 1.9 | 5 |
| 907 | Under-recognition of heart failure in patients with atrial fibrillation and the impact of gender: a UK population-based cohort study. BMC Medicine, 2021, 19, 179. | 2.3 | 5 |
| 908 | Ethnic differences in prevalence of actionable HbA1c levels in UK Biobank: implications for screening. BMJ Open Diabetes Research and Care, 2021, 9, e002176. | 1.2 | 5 |
| 909 | Long term anticoagulation or antiplatelet treatment. BMJ: British Medical Journal, 2001, 323, 233-233. | 2.4 | 5 |
| 910 | Clinical Trials Report: Cardiovascular & Renal: Ongoing and planned clinical trials in chronic heart failure and left ventricular dysfunction. Expert Opinion on Investigational Drugs, 1995, 4, 1069-1080. | 1.9 | 5 |
| 911 | Pathophysiological pathways in patients with heart failure and atrial fibrillation. Cardiovascular Research, 2022, 118, 2478-2487. | 1.8 | 5 |
| 912 | Relationship between a single measurement at baseline of body mass index, glycated hemoglobin, and the risk of mortality and cardiovascular morbidity in type 2 diabetes mellitus. Cardiovascular Endocrinology and Metabolism, 2020, 9, 177-182. | 0.5 | 5 |
| 913 | Revascularization in ischaemic heart failure with preserved ejection fraction: a nationwide cohort study. European Journal of Heart Failure, 2022, 24, 1427-1438. | 2.9 | 5 |
| 914 | Comparing and contrasting risk factors for heart failure in patients with and without history of myocardial infarction: data from <scp>HOMAGE</scp> and the <scp>UK</scp> Biobank. European Journal of Heart Failure, 2022, 24, 976-984. | 2.9 | 5 |
| 915 | Surrogate markers of gut dysfunction are related to heart failure severity and outcome–from the BIOSTAT-CHF consortium. American Heart Journal, 2022, 248, 108-119. | 1.2 | 5 |
| 916 | The COVID-19 pandemic and heart failure: lessons from GUIDE-HF. European Heart Journal, 2022, 43, 2619-2621. | 1.0 | 5 |
| 917 | Influence of Aetiology on the Effects of Treatment in Heart Failure. European Journal of Cardiovascular Prevention and Rehabilitation, 1999, 6, 131-139. | 3.1 | 4 |
| 918 | Are All Î ² -Blockers for Heart Failure the Same?. Circulation, 2000, 102, E41-2. | 1.6 | 4 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 919 | The utility of a comprehensive cardiac magnetic resonance examination for the evaluation of patients with heart failure. Heart, 2004, 90, 1166-1166. | 1.2 | 4 |
| 920 | A comparison between monophasic and biphasic defibrillation for the cardioversion of persistent atrial fibrillation in patients with and without heart failure. International Journal of Cardiology, 2011, 147, 405-408. | 0.8 | 4 |
| 921 | People with disabilities: the forgotten victims of violence. Lancet, The, 2012, 379, 1573-1574. | 6.3 | 4 |
| 922 | Systematic Reporting Bias in Meta-analyses of Trials of Aspirin for the Primary Prevention of Cardiovascular Disease. American Journal of Medicine, 2012, 125, e13. | 0.6 | 4 |
| 923 | Prognostic value of CXCL16 in patients with left ventricular systolic dysfunction and heart failure. International Journal of Cardiology, 2013, 168, 4427-4429. | 0.8 | 4 |
| 924 | Fish Oil vs Olive Oil for Postoperative Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2013, 309, 871. | 3.8 | 4 |
| 925 | Use of cumulative information estimations for risk assessment of heart failure patients. , 2014, , . | | 4 |
| 926 | GuÃa de práctica clÃnica de la ESC 2013 sobre estimulación cardiaca y terapia de resincronización cardiaca. Revista Espanola De Cardiologia, 2014, 67, 58.e1-58.e60. | 0.6 | 4 |
| 927 | When Is it Appropriate to Withdraw Cardiac Resynchronization Therapy? Guesses and Evidence â^—. JACC: Heart Failure, 2015, 3, 337-339. | 1.9 | 4 |
| 928 | Cardiac Resynchronization Therapy Update: Evolving Indications, Expanding Benefit?. Current Cardiology Reports, 2015, 17, 90. | 1.3 | 4 |
| 929 | Influence of case definition on incidence and outcome of acute coronary syndromes. Open Heart, 2016, 3, e000487. | 0.9 | 4 |
| 930 | <scp>PARADIGMâ€HF</scp> : does dose matter?. European Journal of Heart Failure, 2016, 18, 1235-1237. | 2.9 | 4 |
| 931 | New Criteria for LVH Should Be Evaluated Against Age. Journal of the American College of Cardiology, 2017, 70, 2206-2207. | 1.2 | 4 |
| 932 | Clinical and prognostic association of total atrial conduction time in patients with heart failure. Journal of Cardiovascular Medicine, 2019, 20, 442-449. | 0.6 | 4 |
| 933 | Factors influencing women's decisions regarding birth planning in a rural setting in Kenya and their implications for family planning programmes. Journal of Biosocial Science, 2021, 53, 935-947. | 0.5 | 4 |
| 934 | Artificial Intelligence Needs Clinical Intelligence to Succeed. JACC: Heart Failure, 2020, 8, 588-591. | 1.9 | 4 |
| 935 | Disentangling the effects of reproductive behaviours and fertility preferences on child growth in India. Population Studies, 2021, 75, 37-50. | 1.1 | 4 |
| 936 | The association between blood groups and COVIDâ€19 infection: a study from the UK Biobank. Journal of Internal Medicine, 2021, 289, 747-748. | 2.7 | 4 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 937 | Relation Between Thyroid Function and Mortality in Patients With Chronic Heart Failure. American Journal of Cardiology, 2021, 139, 57-63. | 0.7 | 4 |
| 938 | Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, , . | 1.4 | 4 |
| 939 | Acute heart failure (suspected or confirmed): Initial diagnosis and subsequent evaluation with traditional and novel technologies. World Journal of Cardiovascular Diseases, 2013, 03, 290-300. | 0.0 | 4 |
| 940 | Wytyczne ESC dotyczÄce stymulacji serca i terapii resynchronizujÄcej w 2013 roku. Kardiologia Polska, 2013, 71, 133-192. | 0.3 | 4 |
| 941 | Aspirin for Primary and Secondary Prevention of Cardiovascular Disease: Time to Stop?. Thrombosis and Haemostasis, 2022, 122, 311-314. | 1.8 | 4 |
| 942 | Biomarker changes as surrogate endpoints in earlyâ€phase trials in heart failure with reduced ejection fraction. ESC Heart Failure, 2022, 9, 2107-2118. | 1.4 | 4 |
| 943 | Synchronized diaphragmatic stimulation for heart failure using the VisONE system: a firstâ€inâ€patient study. ESC Heart Failure, 0, , . | 1.4 | 4 |
| 944 | The effects of prostacyclin (PGI2) on haematological and haemodynamic parameters, and lung histology in puppies undergoing cardiopulmonary bypass surgery with profound hypothermia. Prostaglandins, Leukotrienes, and Medicine, 1985, 17, 11-29. | 0.8 | 3 |
| 945 | Ancillary diagnostic and therapeutic issues in cardiac failure. Current Opinion in Cardiology, 1992, 7, 408-416. | 0.8 | 3 |
| 946 | A comparison of the effects of the selective peripheralα 1-blocker terazosin with the selectiveβ 1-blocker atenolol on blood pressure, exercise performance and the lipid profile in mild-to-moderate essential hypertension. Clinical Autonomic Research, 1992, 2, 373-381. | 1.4 | 3 |
| 947 | Is there a role for warfarin or aspirin therapy in heart failure?. Heart Failure Reviews, 1997, 1, 271-276. | 1.7 | 3 |
| 948 | Interpretation of Thrombosis Prevention Trial. Lancet, The, 1998, 351, 1205-1206. | 6.3 | 3 |
| 949 | Analysis of failure time hierarchical data in the presence of competing risks with application to oral contraceptive pill use in Egypt. Statistics in Medicine, 2001, 20, 3611-3624. | 0.8 | 3 |
| 950 | Clinical trials update from the European Society of Cardiology Heart Failure meeting: COMET, COMPANION, Tezosentan and SHAPE. European Journal of Heart Failure, 2003, 5, 545-548. | 2.9 | 3 |
| 951 | The value of the imperfect: the contribution of interview surveys to the study of gynaecological ill health. , 0, , 283-321. | | 3 |
| 952 | Can cardiac-resynchronization therapy reduce mortality in patients suffering from advanced chronic heart failure?. Nature Clinical Practice Cardiovascular Medicine, 2004, 1, 10-11. | 3.3 | 3 |
| 953 | Letter to the editor. European Journal of Heart Failure, 2004, 6, 509-509. | 2.9 | 3 |
| 954 | Controlling persistent atrial fibrillation. QJM - Monthly Journal of the Association of Physicians, 2004, 97, 179-180. | 0.2 | 3 |

| # | Article | IF | CITATIONS |
|-----|--|------|-----------|
| 955 | Multidisciplinary interventions in heart failure. Heart, 2005, 91, 849-850. | 1.2 | 3 |
| 956 | Cardiac-Resynchronization Therapy in Heart Failure. New England Journal of Medicine, 2005, 353, 205-206. | 13.9 | 3 |
| 957 | Patients with treatable malignant diseases including heart failure are entitled to specialist care. Cmaj, 2005, 172, 207-209. | 0.9 | 3 |
| 958 | Resource Use and Costs of Treatment With Anticoagulation and Antiplatelet Agents: Results of the WATCH Trial Economic Evaluation. Journal of Cardiac Failure, 2009, 15, 819-827. | 0.7 | 3 |
| 959 | Letter by Begg et al Regarding Article, "The Effects of Vitamin D Supplementation on Physical Function and Quality of Life in Older Heart Failure Patients: A Randomized Controlled Trialâ€: Circulation: Heart Failure, 2010, 3, e24; author reply e25. | 1.6 | 3 |
| 960 | Does aspirin really reduce the risk of colon cancer?. Lancet, The, 2012, 379, 1586. | 6.3 | 3 |
| 961 | Hypoglycaemia in diabetic patients: highly undesirable by cardiologists. European Heart Journal, 2013, 34, 3102-3105. | 1.0 | 3 |
| 962 | Classification of a real live heart failure clinical dataset- Is TAN Bayes better than other Bayes?. , 2014, , | | 3 |
| 963 | QRS morphology as a predictor of the response to cardiac resynchronisation therapy: fact or fashion?. Heart, 2015, 101, 1441-1443. | 1.2 | 3 |
| 964 | Extraâ€cardiac targets in the management of cardiometabolic disease: Deviceâ€based therapies. ESC Heart Failure, 2021, 8, 3327-3338. | 1.4 | 3 |
| 965 | Cardiac Resynchronization for Progressive Heart Failure. JAMA - Journal of the American Medical Association, 2003, 290, 36-c-37. | 3.8 | 3 |
| 966 | Pulmonary and Systemic Responses to Exogenous Endothelin-1 in Patients with Left Ventricular Dysfunction. Journal of Cardiovascular Pharmacology, 1998, 31, S290-S293. | 0.8 | 3 |
| 967 | Time for a proper study of aspirin after a vascular event?. BMJ: British Medical Journal, 2008, 337, a2583-a2583. | 2.4 | 3 |
| 968 | Contraceptive Method Attributes and Married Women's Intention to Use the Pill or the Injectable in Rural Bangladesh. International Perspectives on Sexual and Reproductive Health, 2018, 44, 157. | 3.8 | 3 |
| 969 | Synchronized diaphragmatic stimulation: a case report of a novel extraâ€cardiac intervention for chronic heart failure. ESC Heart Failure, 2022, , . | 1.4 | 3 |
| 970 | Changes in clinical and imaging variables during withdrawal of heart failure therapy in recovered dilated cardiomyopathy. ESC Heart Failure, 2022, 9, 1616-1624. | 1.4 | 3 |
| 971 | The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial. Journal of Cardiac Failure, 2021, , . | 0.7 | 3 |
| 972 | ACE inhibitors: current understanding and future directions. Heart, 1994, 72, S1-S1. | 1.2 | 2 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 973 | The Concept of Cardioreparation: Part 2. Medical Implications of Cardioreparation. European Journal of Cardiovascular Prevention and Rehabilitation, 1996, 3, 287-293. | 3.1 | 2 |
| 974 | Combination drug therapy in chronic heart failure: is treatment part of the problem in heart failure?. , 1997, 11, 297-303. | | 2 |
| 975 | Economic implications of the Total Ischaemic Burden Bisoprolol Study (TIBBS) follow-up. Journal of Medical Economics, 1998, 1, 263-280. | 1.0 | 2 |
| 976 | Focus on Carvedilol for Heart Failure. , 1999, 4, 5-6. | | 2 |
| 977 | Disruption of the relationship between renin and atrial natriuretic peptide early in the course of ventricular dysfunction. European Journal of Heart Failure, 1999, 1, 371-377. | 2.9 | 2 |
| 978 | Implantable left ventricular assist systems: clinical trials. European Journal of Heart Failure, 2000, 2, 19-21. | 2.9 | 2 |
| 979 | Beta-blockers for heart failure. , 2000, , . | | 2 |
| 980 | Myocardial dysfunction: hibernation and remodelling. Lancet, The, 2003, 362, 1416-1417. | 6.3 | 2 |
| 981 | Meta-analysis does not show that cardiac resynchronisation reduces all-cause mortality. International Journal of Cardiology, 2005, 103, 230-231. | 0.8 | 2 |
| 982 | Role of angiotensin receptor blockers in the prevention and management of ischaemic stroke. European Journal of Neurology, 2007, 14, 1201-1209. | 1.7 | 2 |
| 983 | Aspirin in the primary prevention of vascular disease. Lancet, The, 2009, 374, 878. | 6.3 | 2 |
| 984 | An atrial mass. Journal of Cardiovascular Medicine, 2012, 13, 769-770. | 0.6 | 2 |
| 985 | Increasing knowledge and changing views in cardiac resynchronization therapy. Heart Failure Reviews, 2012, 17, 721-725. | 1.7 | 2 |
| 986 | The intersection of atrial fi brillation and heart failure in a hospitalised population. Acta Cardiologica, 2013, 68, 395-402. | 0.3 | 2 |
| 987 | The remarkable effect of ivabradine in two adolescents with dilated cardiomyopathy. Clinical Research in Cardiology, 2014, 103, 847-849. | 1.5 | 2 |
| 988 | Is the Way to a Man's Heart Through HisÂStomach?. Journal of the American College of Cardiology, 2014, 64, 1103-1105. | 1.2 | 2 |
| 989 | 45â€Role of Natriuretic Peptides in Screening of Cardiac Dysfunction in Older Patients with Type-2 Dibetes Mellitus. A Report from Sica-diabetes Study (FP7/2007–2013/241558). Heart, 2014, 100, A25.1-A25. | 1.2 | 2 |
| 990 | CRT for Heart Failure and ESRD. Journal of the American College of Cardiology, 2015, 66, 2630-2632. | 1.2 | 2 |

| # | Article | IF | CITATIONS |
|------|--|-----|-----------|
| 991 | 161â€Use of colchicine in cardiovascular diseases – a systematic review. Heart, 2015, 101, A91.3-A92. | 1.2 | 2 |
| 992 | Classification of Aortic Stenosis by Flow and Gradient Patterns Provides Insights into the Pathophysiology of Disease. Angiology, 2016, 67, 664-669. | 0.8 | 2 |
| 993 | Potential role for clinical calibration to increase engagement with and application of home telemonitoring: a report from the HeartCycle programme. ESC Heart Failure, 2017, 4, 66-70. | 1.4 | 2 |
| 994 | Stem cell therapy for dilated cardiomyopathy. The Cochrane Library, 2019, , . | 1.5 | 2 |
| 995 | A global perspective of racial differences and outcomes in patients presenting with acute heart failure. American Heart Journal, 2022, 243, 11-14. | 1.2 | 2 |
| 996 | Applying evidence-based device care in cardiovascular patients: which patient with heart failure and what device?. Journal of the Royal College of Physicians of Edinburgh, The, 2010, 40, 229-239. | 0.2 | 2 |
| 997 | What does it take to make integrated care work?. International Journal of Integrated Care, 2016, 16, 113. | 0.1 | 2 |
| 998 | ??-Blockers for Chronic Heart Failure. Journal of Cardiovascular Pharmacology, 1998, 32, S52-S60. | 0.8 | 2 |
| 999 | Influence of body mass on risk prediction during cardiopulmonary exercise testing in patients with chronic heart failure. Experimental and Clinical Cardiology, 2012, 17, 179-82. | 1.3 | 2 |
| 1000 | No influence of spironolactone on plasma concentrations of angiotensin-converting enzyme 2: Findings from the HOMAGE randomized trial. Archives of Cardiovascular Diseases, 2021, 114, 814-817. | 0.7 | 2 |
| 1001 | Maintaining Success for Patients With Dilated Cardiomyopathy and Remission of HeartÂFailure. JACC Basic To Translational Science, 2022, 7, 500-503. | 1.9 | 2 |
| 1002 | Dynamic risk stratification using Markov chain modelling in patients with chronic heart failure. ESC Heart Failure, 0, , . | 1.4 | 2 |
| 1003 | Ancillary therapy for heart failure. Current Opinion in Cardiology, 1991, 6, 373-378. | 0.8 | 1 |
| 1004 | Heart Failure - taking the lead. European Journal of Heart Failure, 1999, 1, 119-119. | 2.9 | 1 |
| 1005 | The CHARM programme. Lancet, The, 2003, 362, 1675-1676. | 6.3 | 1 |
| 1006 | Carvedilol was more effective than metoprolol tartrate for lowering mortality in chronic heart failure. Evidence-Based Medicine, 2004, 9, 14-14. | 0.6 | 1 |
| 1007 | Comprehensive adrenergic receptor blockade with carvedilol is superior to beta-1-selective blockade with metoprolol in patients with heart failure: COMET. Current Heart Failure Reports, 2004, 1, 82-88. | 1.3 | 1 |
| 1008 | Consistent survival benefit of carvedilol over metoprolol irrespective of baseline characteristics of heart failure patients – mode of death evaluation in COMET. Journal of Cardiac Failure, 2004, 10, S84. | 0.7 | 1 |

| # | Article | IF | CITATIONS |
|------|--|-----|-----------|
| 1009 | Response from editor to letter to the editor-Alternative approaches to the management of heart failure: Editors response. European Journal of Heart Failure, 2004, 6, 517-518. | 2.9 | 1 |
| 1010 | Diagnosing heart failure in primary care: lessons from EPICA. European Journal of Heart Failure, 2004, 6, 793-794. | 2.9 | 1 |
| 1011 | Letter from the outgoing Editor-in-Chief of the European Journal of Heart Failure. European Journal of Heart Failure, 2005, 7, 1-2. | 2.9 | 1 |
| 1012 | Hierarchical cardiac MRI segmentation using shaped region-interface descriptors. International Congress Series, 2005, 1281, 363-368. | 0.2 | 1 |
| 1013 | Are There Clinically Important Differences Between Beta-Blockers in Heart Failure?. Heart Failure Clinics, 2005, 1, 57-66. | 1.0 | 1 |
| 1014 | Randomized trials are also essential for device therapy: reply. Journal of Internal Medicine, 2006, 260, 282-283. | 2.7 | 1 |
| 1015 | How many patients need cardiac resynchronization therapy?The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology European Heart Journal, 2006, 27, 251-252. | 1.0 | 1 |
| 1016 | Cardiac resynchronization therapy: redefining the role of device therapy in heart failure. Expert Review of Pharmacoeconomics and Outcomes Research, 2006, 6, 455-469. | 0.7 | 1 |
| 1017 | Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro) BNP. Europace, 2007, 9, 147-147. | 0.7 | 1 |
| 1018 | Fighting against sudden death: A single or multidisciplinary approach. Journal of Interventional Cardiac Electrophysiology, 2007, 17, 205-210. | 0.6 | 1 |
| 1019 | Is the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) the Answer to the Cholesterol Paradox in Heart Failure?. Congestive Heart Failure, 2008, 14, 55-55. | 2.0 | 1 |
| 1020 | Relationship of high sensitivity C reactive peptide (hsCRP) to prognosis and other prognostic markers in outpatients with heart failure. American Heart Journal, 2008, 155, e9. | 1.2 | 1 |
| 1021 | Smoking cessation in heart failure: easier said than done. European Heart Journal, 2009, 30, 624-625. | 1.0 | 1 |
| 1022 | Antiplatelet therapy for ACS: a house in need of a spring clean. The Prescriber, 2009, 20, 7-8. | 0.1 | 1 |
| 1023 | The effectiveness of enhanced external counterpulsation (EECP) in patients suffering from chronic refractory angina previously treated with transmyocardial laser revascularisation. International Journal of Cardiology, 2013, 168, 4383-4385. | 0.8 | 1 |
| 1024 | 59â€Is Presentation of Acute Heart Failure Patients Linked to Mortality?. Heart, 2014, 100, A34.1-A34. | 1.2 | 1 |
| 1025 | Is the Epidemic of Heart Disease Really Over or Just Evolving?. American Journal of Medicine, 2015, 128, e17. | 0.6 | 1 |
| 1026 | POPULATION GROWTH, EMPLOYMENT, AND LIVELIHOODS: THE TRIPLE CHALLENGE. Journal of Demographic Economics, 2017, 83, 51-61. | 1.2 | 1 |

| # | Article | IF | CITATIONS |
|------|--|------------|-----------|
| 1027 | Exploring the relation between changes in NT-proBNP and renal function in patients with suspected heart failure using structural equation modelling. International Journal of Cardiology, 2017, 233, 67-72. | 0.8 | 1 |
| 1028 | 50â€Incremental diagnostic value of cardiovascular magnetic resonance in young adult survivors of sudden cardiac arrest. Heart, 2017, 103, A39-A39. | 1.2 | 1 |
| 1029 | A Randomized Study Comparing Rivaroxaban with Placebo in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure: The COMMANDER HF study. Journal of Cardiac Failure, 2018, 24, 811. | 0.7 | 1 |
| 1030 | Psychosocial factors and mortality in patients with heart failure: reply. European Journal of Heart Failure, 2018, 20, 1244-1244. | 2.9 | 1 |
| 1031 | EFFECT OF OMECAMTIV MECARBIL IN PATIENTS WITH ATRIAL FIBRILLATION AND HEART FAILURE WITH REDUCED EJECTION FRACTION: RESULTS FROM COSMIC-HF. Journal of the American College of Cardiology, 2019, 73, 691. | 1.2 | 1 |
| 1032 | Long-Term Trends in Reproductive Behavior Among Young Women in Four Countries, 1995–2009. Journal of Adolescent Health, 2019, 64, 201-210. | 1.2 | 1 |
| 1033 | Structural heart disease, cardiac dysfunction and heart failure: the ambiguity of a definition. European Journal of Preventive Cardiology, 2021, 28, 921-923. | 0.8 | 1 |
| 1034 | A qualitative exploration of participant and investigator perspectives from the TREDâ€HF trial. ESC Heart Failure, 2021, 8, 3760-3768. | 1.4 | 1 |
| 1035 | The Epidemiology of Heart Failure. , 2008, , 9-26. | | 1 |
| 1036 | 43 Antithrombotic agents. , 2011, , . | | 1 |
| 1037 | The year in cardiology: heart failure†The year in cardiology 2019. Cardiologia Croatica, 2020, 15, 167-188. | 0.0 | 1 |
| 1038 | Only people with increased plasma concentrations of natriuretic peptides should be included in outcome trials of diabetes, cardiovascular and kidney disease: implications for clinical practice. European Journal of Heart Failure, 2022, 24, 678-680. | 2.9 | 1 |
| 1039 | Trends in Reproductive Behavior among Young Single Women in Colombia and Peru: 1985-1999. Demography, 2003, 40, 659. | 1.2 | 1 |
| | | | |
| 1040 | Maintaining Public Trust in Medical Advice—Could Less Be More?. JAMA Network Open, 2022, 5, e2211113. | 2.8 | 1 |
| 1040 | Maintaining Public Trust in Medical Adviceâ€"Could Less Be More?. JAMA Network Open, 2022, 5, e2211113. Heart failure: age is no excuse for complacency. European Journal of Heart Failure, 2022, 24, 1063-1065. | 2.8 2.9 | 1 |
| | | | |
| 1041 | Heart failure: age is no excuse for complacency. European Journal of Heart Failure, 2022, 24, 1063-1065. | 2.9 | 1 |

| # | Article | IF | CITATIONS |
|------|--|-----|-----------|
| 1045 | Perindopril. Drugs, 2002, 62, 1378-1379. | 4.9 | 0 |
| 1046 | Potential causes for renal dysfunction in heart failure. Journal of Cardiac Failure, 2003, 9, S74. | 0.7 | 0 |
| 1047 | The CHARM programme. Lancet, The, 2003, 362, 1679. | 6.3 | 0 |
| 1048 | Pain Management in Patients With Osteoarthritis. JAMA - Journal of the American Medical Association, 2003, 290, 36. | 3.8 | 0 |
| 1049 | Integrating qualitative and quantitative methods in research on reproductive health. , 0, , 360-390. | | 0 |
| 1050 | Cardiac Resynchronization for Progressive Heart Failure. JAMA - Journal of the American Medical Association, 2003, 290, 36. | 3.8 | 0 |
| 1051 | A Happy and Prosperous New Year to All Our Readers!. European Journal of Heart Failure, 2003, 5, 1-1. | 2.9 | 0 |
| 1052 | Impact on mortality of plasma NT-proBNP in chronic heart failure in patients treated with beta-blockers. results from COMET. Journal of Cardiac Failure, 2004, 10, S77. | 0.7 | 0 |
| 1053 | Effects of carvedilol versus metoprolol on hemostasis and fibrinolysis in patients with chronic heart failure. Journal of Cardiac Failure, 2004, 10, S78-S79. | 0.7 | 0 |
| 1054 | 234 An international acute heart failure trial may be more representative of the united states population than united states-based studies: an analysis of the randomized interventions with tezosentan (RITZ-1) trial. Journal of Cardiac Failure, 2004, 10, S81. | 0.7 | 0 |
| 1055 | Prognostic impact of symptoms in chronic heart failure - results from COMET. Journal of Cardiac Failure, 2004, 10, S83. | 0.7 | 0 |
| 1056 | Cost effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial: reply. European Heart Journal, 2005, 27, 1125-1126. | 1.0 | 0 |
| 1057 | AB33-2. Heart Rhythm, 2006, 3, S68. | 0.3 | 0 |
| 1058 | AB43-1. Heart Rhythm, 2006, 3, S88-S89. | 0.3 | 0 |
| 1059 | P4-97. Heart Rhythm, 2006, 3, S251. | 0.3 | 0 |
| 1060 | Papel de los ARA-II en el tratamiento de la insuficiencia cardiaca: ¿qué dicen las guÃas de práctica clÂnica?. Revista Espanola De Cardiologia Suplementos, 2006, 6, 58C-72C. | 0.2 | 0 |
| 1061 | Cardiac resynchronisation therapy upgrade and occurrence of ventricular arrhythmia. Heart, 2008, 94, 793-793. | 1.2 | 0 |
| 1062 | Response to Letter Regarding Article, "Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial― Circulation, 2009, 120, . | 1.6 | 0 |

| # | Article | IF | CITATIONS |
|------|---|-----|-----------|
| 1063 | Prognostic Significance of NTpro-BNP in Patients Having Heart Failure With Preserved Ejection Fraction, Compared With Those Having Reduced Ejection Fraction. Journal of Cardiac Failure, 2010, 16, S88-S89. | 0.7 | 0 |
| 1064 | Unmasking the truth. BMJ Case Reports, 2011, 2011, bcr0720103193-bcr0720103193. | 0.2 | 0 |
| 1065 | Outcome of Transcatheter Mitral Valve Clip for the Management of Mitral Regurgitation in High Risk Group Patients Unsuitable for Surgical Intervention. American Journal of Cardiology, 2013, 111, 58B. | 0.7 | 0 |
| 1066 | Improving Quality of Life and Functional Capacity in Atrial Fibrillation and Congestive Heart Failure. Journal of the American College of Cardiology, 2013, 61, 2196-2197. | 1.2 | 0 |
| 1067 | 53â€Heart Rate as a Therapeutic Target in Heart Failure: Analysis of 1000 Consecutive Outpatient Appointments to a Heart Failure Clinic. Heart, 2014, 100, A30.2-A31. | 1.2 | Ο |
| 1068 | Prediction of Post-Discharge Outcomes for Patients Hospitalized with Heart Failure: Results from PROTECT. Journal of Cardiac Failure, 2015, 21, S64. | 0.7 | 0 |
| 1069 | Letter by Mareev et al Regarding Article, "Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Womenâ€: Circulation: Heart Failure, 2016, 9, . | 1.6 | 0 |
| 1070 | 002â€Sudden cardiac death risk stratification in patients with mild dilated cardiomyopathy. Heart, 2017, 103, A2.1-A2. | 1.2 | 0 |
| 1071 | CARDIOVASCULAR MAGNETIC RESONANCE IN SURVIVORS OF SUDDEN CARDIAC ARREST: 14 YEAR EXPERIENCE FROM A TERTIARY REFERRAL CENTRE IN THE UNITED KINGDOM. Journal of the American College of Cardiology, 2017, 69, 491. | 1.2 | 0 |
| 1072 | Effect of Patiromer on Serum K+ in Hyperkalemic Patients with Heart Failure (HF): Pooled Results From the AMETHYST-DN, OPAL-HK and TOURMALINE Trials. Journal of Cardiac Failure, 2017, 23, S21. | 0.7 | 0 |
| 1073 | What Do Cardiology and Homeopathy Have in Common?. JACC: Heart Failure, 2017, 5, 611-614. | 1.9 | 0 |
| 1074 | 127â€Relationship between plasma concentrations of b-type natriuretic peptide and exercise capacity in hypertrophic cardiomyopathy. Heart, 2017, 103, A96-A97. | 1.2 | 0 |
| 1075 | Reply. Journal of the American College of Cardiology, 2018, 71, 105. | 1.2 | 0 |
| 1076 | Losing Track by Tracking Speckles. JACC: Cardiovascular Imaging, 2018, 11, 1038-1039. | 2.3 | 0 |
| 1077 | 91â <prophylactic ,="" .<="" 2018,="" cancer="" carvedilol="" doxorubicin.="" dysfunction="" in="" of="" patients="" prevent="" td="" to="" treated="" use="" ventricular="" with=""><td></td><td>0</td></prophylactic> | | 0 |
| 1078 | When can heart failure treatment be stopped safely? – Authors' reply. Lancet, The, 2019, 394, 217-218. | 6.3 | 0 |
| 1079 | 30 Fertility Regulation. Handbooks of Sociology and Social Research, 2019, , 793-817. | 0.1 | Ο |
| 1080 | 77â€Contemporary prognosis of patients hospitalised with a primary diagnosis of heart failure: the national heart failure audit of england & wales. , 2019, , . | | 0 |

| # | Article | IF | CITATIONS |
|------|---|-----|-----------|
| 1081 | 78â€Effects of short-term omission or increase in loop diuretic therapy on cardiac function in patients with chronic, stable heart failure. , 2019, , . | | 0 |
| 1082 | 82â€People prescribed loop diuretics have a poor outcome even without a diagnostic label of heart failure. , 2019, , . | | 0 |
| 1083 | 91â€The relation between thyroid dysfunction and mortality in patients with chronic heart failure. , 2019, , . | | 0 |
| 1084 | Implantable device monitoring versus usual care for managing individuals with heart failure. The Cochrane Library, 2019, , . | 1.5 | 0 |
| 1085 | Homage Proof of Concept Trial of Spironolactone for the Prevention of Heart Failure. Journal of Cardiac Failure, 2019, 25, 939. | 0.7 | 0 |
| 1086 | Exercise Training for Heart Failure With Preserved Ejection Fraction (ExTraMATCH III): Protocol for an Individual Patient Data Meta-Analysis. Bioengineered, 2021, 10, 3-11. | 1.4 | 0 |
| 1087 | Correspondence to <i>European Heart Journalâ€"Quality of Care and Clinical Outcomes</i> in response to paper by Thomas, M. <i>et al.</i> 2021: Predicting the EQ-5D from the Kansas City Cardiomyopathy Questionnaire (KCCQ) in patients with heart failures. European Heart Journal Quality of Care & amp: Clinical Outcomes, 2021, 7, e7-e7. | 1.8 | 0 |
| 1088 | Use of Social Media by Cardiovascular Health Care Professionals. JACC: Cardiovascular Imaging, 2021, 14, 1680-1682. | 2.3 | 0 |
| 1089 | The European Journal of Heart Failure; update on the story so far!. European Journal of Heart Failure, 2002, 4, 225-226. | 2.9 | 0 |
| 1090 | Decrease in fatty acid oxidation increases tolerance of the ageing heart to ischaemic injury. FASEB Journal, 2006, 20, . | 0.2 | 0 |
| 1091 | Angiotensin receptor blockers for chronic heart failure. , 2006, , 127-171. | | 0 |
| 1092 | Classification of the Level of Evidence in International Guidelines for Acute and Chronic Heart Failure. , 2008, , 885-891. | | 0 |
| 1093 | Editorialists' reply. BMJ: British Medical Journal, 2010, 341, c4991-c4991. | 2.4 | 0 |
| 1094 | Effect of medications on cardiac output. Developments in Cardiovascular Medicine, 1993, , 225-250. | 0.1 | 0 |
| 1095 | Management of coronary artery disease. Developments in Cardiovascular Medicine, 1996, , 187-208. | 0.1 | 0 |
| 1096 | The year in cardiology 2019: heart failure. Revista Romana De Cardiologie, 2020, 30, 185-204. | 0.0 | 0 |
| 1097 | Chronic aspirin is effectiveif data are massaged sufficiently. BMJ, The, 2002, 324, 295. | 3.0 | 0 |
| 1098 | PO-628-08 RESPONSE TO CRT IS DIFFERENT IN PATIENTS WITH IVCD COMPARED TO RBBB: A PATIENT LEVEL META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. Heart Rhythm, 2022, 19, S160. | 0.3 | 0 |